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CHRONIC KIDNEY DISEASE AND PLASMA HOMOCYSTEINE LEVEL 
ABSTRACT  :  
    Background :  . Chronic kidney disease(CKD) is a very common condition 
result of different etiologies.There are reports in literature indicating that chronic 
kidney disease  leads  hyperhomocysteinemia which contributes to increased 
cardiovascular morbidity and mortalities. Reduction  of homocysteine level  may 
help to decrease the cardiovascular morbidity and mortality which are leading 
cause of death in chronic kidney disease patients  
Material and methods : 50 patients with CKD admitted to Thanjavur medical 
college  were selected for study and their fasting plasma homocysteine level were 
measured. Patients who are having acute kidney injury, who are current 
smokers,alcohol consumers , who are having liver diseases , who are diabetic are 
excluded from study. Normal plasma homocysteine level was considered to be 
below 15 umol/litre .    
Observations & Results :Of the 50 patients 37 were males 13 were females . 34  
patients were in age range of   41-60 .  36 patients were in stage 5 CKD , 11 were 
in stage 4 CKD , 3 were in stage 3 CKD . Hyperhomocysteinemia was observed in 
78 % of CKD patients . 94.87% had mild hyperhomocysteinemia .  End stage renal 
disease patients had increased prevalence of hyperhomocysteinemia . 
 There was not much difference in hyperhomocysteinemia in patients who are on 
dialysis and who are not on dialysis  
Conclusion: Hyperhomocysteinemia  is  highly  prevalent in CKD patients.  
Key words : hyperhomocysteinemia , Chronic kidney disease , homocysteine     
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INTRODUCTION 
    Chronic kidney disease is a common age related and risk factor associated  
morbidity affecting lot  of people  where there is gradual reduction in 
functioning mass of kidney due to loss of nephrons that results in decreased 
excretion of metabolic waste products from the body and their accumulation 
in the body leading to constellation of symptoms resulting from fluid 
retention and extravasation causing pedal edema , acute pulmonary edema 
and other volume overload signs and symptoms along with retention of 
uremic toxins with consequent signs and symptoms . Chronic kidney disease 
predisposes to number of systemic abnormalities . One of the leading causes 
of morbidity and mortality in chronic kidney disease patients is 
cardiovascular system involvement. A number of causes have been 
postulated to increase susceptibility for cardiac diseases  and death due to 
cardiac diseases in chronic kidney disease affected persons. One among 
those is hyperhomocysteinemia in Chronic kidney disease (CKD).  
Hyperhomocysteinemia results from number of causes . Major causes for 
hyperhomocysteinemia  in CKD are decreased excretion of homocysteine 
by diseased kidney and altererd metabolism of homocysteine in uremic 
mileu. Many studies have shown significant association and  negative 
correlation  between decrease in Glomerular filtration rate and increase in 
homocysteine level .Many studies are ongoing to find out whether 
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decreasing homocysteine in CKD patients will decrease cardiovascular 
morbidity and mortality. So in this study an attempt is made to find out 
association and correlation between decreased renal function and an 
increase in homocysteine level .  
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AIMS AND OBJECTIVES 
1. To study homocysteine level in patients with Chronic kidney disease  
2. To study the association  and correlation between  decrease in renal 
function and increase in homocysteine level in chronic kidney disease 
patients  
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REVIEW OF LITERATURE 
Kidneys are vital organs of human body .Each kidney situated posteriorly 
behind the peritoneum on each side of the vertebral column 1. Superiorly 
they are at the  superior  border of 12th  dorsal  vertebra ,inferiorly at the 3rd 
lumbar vertebra , left is somewhat  superior to the right .Left usually little 
longer and smaller than right and lies closer to the  median plane . Each 
kidney is typically  3cm in anteroposterior direction, 11cm in length, 6cm 
width .Average weight of human kidney is 150 gm in men and 135 gm in 
women. Nephrons are functional unit of kidneys .It consists of renal tubule 
and its associated  glomerulus. Each human kidney has approximately 1 
million nephrons .There are different types of  nephrons .They are   
nephrons in the cortex  and nephrons in  Juxtamedullary    region.  Nephrons  
in cortex have short loop of Henle  where as nephrons in  juxtamedullary  
region  have long loop of Henle . In humans 15% of nephrons are 
juxtamedullary  nephrons . 
Functions of kidney2 : 
 Main work of kidney is removal of waste products produced due to 
metabolism . It does that function through a complex process of  glomerular  
filtration , tubular  absorption ,tubular secretion . Glomerular  filtration is 
plasma ultrafiltrate formed due to filtration of blood at glomeruli. 
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Glomerular  filtration rate(GFR) is one of the important indicators of well-
being of kidney. As kidney function deteriorates  GFR also decreases.  
Other important functions of kidney : 
       1.Water and electrolyte balance . 
Kidney regulates water content of body and electrolyte content . If 
kidney is not functioning normally volume overload or dehydration may 
develop. Electrolyte imbalances like hyponatremia , hyperkalemia and other  
acid base disturbances may develop in kidney malfunctioning   
        2. Endocrine function :  
                            Kidney produces hormones  like erythropoietin which 
helps in erythropoiesis. Kidneys also produce 1,25-dihydroxycholecalciferol 
which helps in  Vitamin  D metabolism and calcium homeostasis in body. In 
kidney diseases calcium, phosphorous and Vitamin  D metabolisms are 
altered which leads to lot of complications .Kidney produces renin which 
helps in maintenance of electrolyte in the body and blood pressure control .  
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CHRONIC KIDNEY DISEASE3: 
            Chronic kidney disease is an entity which encompasses a spectrum  
of  derangement of kidney function in which there is progressive decrease in 
functioning  nephrons  and a progressive reduction in glomerular filtration 
rate. National kidney Foundation (Kidney Dialysis Outcome Quality 
Initiative ) classifies CKD into 6 stages depending on GFR  
 
              CLASSIFICATION OF CHRONIC KIDNEY DISEASE 
Stage GFR ml/min per 1.73m2 
0 >90* 
1 >90# 
2 60-89 
3 30-59 
4 15-29 
5 <15 
*with risk factors for CKD 
#with demonstrated kidney damage (e.g persistent proteinuria, abnormal 
sediment ,abnormal  urine and blood chemistry , abnormal imaging studies) 
In contrast to chronic kidney disease chronic renal failure refers to the 
process of continuing  significant  irreversible decrease  in nephron number 
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and classically referring  to CKD stage 3-5 . End stage renal disease  
represents a stage where accumulation of toxins ,fluid and electrolytes 
normally excreted by kidney leads to uremic syndrome .This constellation 
of symptoms and signs  will cause  mortality   if not harmful toxins  are 
taken out of body by renal replacement therapy in the form of either  by 
renal transplantation or dialysis  . 
 
Formulas for calculating GLOMERULAR FILTRATION RATE4: 
                   1.  MODIFICATION OF DIET IN RENAL DISEASE STUDY  
which incorporates persons serum creatine and age 
                   2.  Cockcroft Gault equation   
Estimated creatinine clearance =  
 (140 -age ) body weight =ml/min 
                                                                         72*plasma creatinine  
                                                                                                  
Multiply 0.85 for women 
Normal GFR  is around 125ml/min per 1.73 m2  
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Pathophysiology of chronic kidney disease : 
            Consists of two types of mechanisms of damage : 
                         1.First there will be start of mechanism specific to the cause 
of particular disease  (abnormalities which affect kidney development  
genetically  or integrity of kidney ,deposition of immunoglobulin  and   
glomerulonephritis causing inflammation  or tubular or interstitial diseases 
caused by certain types of toxins). 
                 2.A collective and compensatory mechanisms  of progressive  
hyperfiltration  and  hypertrophy of remaining functioning  nephrons  that  
happens in all kidney diseases leading to nephron loss whatever may be the 
etiology causing such events   
 Response to decrease  in number of nephrons   are  mediated by 
vasoactive substances like growth factors and cytokines . Ultimately  these  
short term adjusting   mechanisms of hypertrophy and hyperfiltration  
become difficult  as the intraglomerular hypertension  and increased flow 
through remaining nephrons  predisposes to loss of glomerular architecture 
associated with thickening  and loss  of existing  nephrons . Elevated  
intrarenal action of renin  angiotensin system  is thought to contribute both 
to the initial adoptive increased filtration and to subsequent maladaptive  
hypertrophy and thickening of nephrons . Sclerosis develops due to action 
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of transforming growth factor beta. Because of this mechanism an acute 
short lasting damage to the kidney leads to progressive decrease  in kidney  
function over many years and lead to the chronic kidney disease.  
            In chronic kidney disease there is progressive decline in the number 
of functioning nephrons and progressive decline in renal functioning . Up to 
some extent remaining nephrons compensate for the function and ultimately 
lead to decomponsated state leading to uremic syndrome . 
Response of kidney to reduction in numbers of functioning nephrons : 
          Loss in the many functioning nephrons produces an increase in renal 
flow. Glomerular hyperfiltration which is the result of increased 
vasoconstriction in the post glomerular efferent arterioles compared to 
afferent arterioles increasing intraglomerular capillary pressure and filtration 
fraction .Persistent intraglomerular hypertension is associated with 
progressive nephron destruction . Hormonal and metabolic factors 
mediating hyperfiltration not fully understood. A number of 
vasoconstrictive and vasodilator substances have been implicated. One of 
the important factor is angiotensin 2. Angiotensin 2 causes vasoconstriction 
of efferent arterioles . Studies have shown that angiotensin converting 
enzyme 2 inhibitors will decrease  intraglomerular capillary pressure and 
decrease proteinuria and  slow the rate of nephron destruction .The 
vasoconstrictive agent endothelin has been implicated in hyperfiltration and 
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afferent vasodilatation has been attributed to local prostaglandins and 
release of endothelium derived growth factor that is nitric oxide .  
Hyperfiltration may be mediated by resetting of kidney’s intrinsic 
autoregulatory mechanism of glomerular filtration by a tubuloglomerular 
feedback system . Feedback originates from macula densa and modulates 
the renal blood flow and glomerular  filtration . 
Even with loss of functioning nephrons kidneys will maintain glomerular 
and tubular balance by which the remaining tubules adjust to increase in  
single nephron  glomerular filtration  with appropriate modification  in the 
reabsorption or excretion of filtered water and solutes in order to maintain 
the homeostasis . Glomerular balance results from both increase in tubular  
size  and from regulatory adjustments in tubular oncotic pressure or solute 
transport along the proximal tubule . Some studies indicate these alterations 
in tubule size and function may themselves be maladaptive and as a trade 
off predispose to further tubule injury .  
Risk factors for CKD : 
                             Throughout the world  most common cause of  CKD  is     
diabetes mellitus  .Other risk etiology for CKD are  
 Hypertension and hypertensive nephropathy  
 Glomerulonephritis  
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• Primary glomerular diseases with hypertension  
• Vascular and ischemic renal disease  
 polycystic kidney disease 
 Other cystic and tubulointerstitial nephropathy 
 
Identification of  risk factors for CKD : 
         Predisposing  Factors include   
• Increasing age  
• Increased blood pressure  
• Poor blood glucose control and uncontrolled diabetes 
mellitus  
• Autoimmune disease  
• Family history of renal disease 
• Previous episode of acute kidney injury 
• Presence of proteinuria  
• Presence of abnormal urinary sediment  
• Structural abnormalities of urinary tract  
Recently lot of developments have taken place in the field of genetics to 
find out specific loci for CKD . One among those is  APOL1  gene which 
has been associated with CKD in west African ancestry  
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As CKD worsens GFR  decreases . From third decade onwards annual 
decline in GFR from mean GFR 125 ml/min is 1ml/min /year per 1.73m2. 
GFR is lower in women compared with men . 
Measurement of albumin in urine helps in identification of nephron loss 
especially in patients with chronic glomerular disease .  
Measurement of protein to creatinine ratio also helps in finding out renal 
disease Persistent of more than 17 mg of albumin per gram of creatinine  in 
adult male and more than 25 mg of albumin per gram of creatinine in 
women usually signifies chronic renal damage . 
Microalbuminuria is excretion of 30 to 300 mg of albumin per day is very 
useful indicator of presence of renal disease . Microalbuminuria is a marker 
of microvascular disease of the  kidney .  
Staging of CKD can be done according to  GFR  as stated above . 
In Stage 1 & 2 even though there is decrease in GFR,  are not associated 
with any symptoms  but patient may present with symptoms related to 
etiology of CKD .For example if patient has autosomal dominant polycystic 
kidney disease he may present with complaints related to hypertension or a 
patient with nephritic syndrome may present with symptoms like 
generalized edema due to protein loss .If GFR further decreases patient 
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enters to stage 3  and then 4 then 5 . During these stages patient present with 
symptoms related to renal insuffiency .  
  Variety of manifestations due to renal insuffiency may develop . 
Common during initial stages are easy fatigability, decreasing appetite ,with 
progressive malnutrition . 
 Later patient may develop imbalance in calcium ,phosphorous , Vit D 
metabolism , sodium , potassium, water and acid base imbalance . 
Eventually patient will land up in UREMIC syndrome   . 
 Pathophysiology and biochemistry of Uremia: 
          Eventhough  blood urea and serum creatinine are commonly used to  
find out excretory capacity of kidney there are many more waste products of 
metabolism are accumulated In body which are responsible for uremic 
syndrome  
To name few they are  
 Guanidine compounds  
 Urate  
 Hippurate  
 Products of nucleic acid metabolism  
 Polyamines 
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 Myoinositol  
 Phenols  
 Benzoates  
 Indoles  
  Middle molecules with molecular mass between 50 to 500 Da  are also 
retained and contributes to symtoms related to uremia and leads to 
morbidity and mortality . 
                   Above lines show that  blood urea and serum creatinine are 
easily measurable compounds but symptoms of uremia may be caused by 
variety of compounds  
Functions of kidney like metabolic and endocrine functions deranged in 
CKD and contributes to morbidity and mortality . 
Plasma levels of many hormones are altered in CKD as well as metabolism 
of protein sugar and fat metabolism  
Parathormone  ,FGF -23, insulin ,glucagon ,steroid hormone , testosterone 
and estrogen ,prolactin levels and metabolism of these hormones altered in 
CKD  
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Common  causes of end stage renal disease5 : 
Disease  Proportion  Comments  
Congenital and 
inherited 5% 
Polycystic kidney 
Alports syndrome 
Renovascular disease 5% Atheromatous disease 
Hypertension 5-20%  
Glomerular disease 10-20% Ig A NEPHROPATHY 
Interstitial disease 20-30% Often drug induced 
Systemic inflammatory 
disease 5-10% 
Lupus nephritis  , 
vasculitis 
Diabetes mellitus 20-40%  
Unknown cause 5-20% 
 
 
Clinical manifestation of CKD  :                                          
          Uremia causes dysfunction in almost all organs .Dialysis to some 
extent helps to decrease symptoms related to uremia but many conditions 
are not reversible with dialysis . 
Fluid and electrolyte and acid base imbalance  :  
There  will be retention of sodium and water in body in  CKD. In normal 
person urine output matches intake of fluid . But in CKD patients there will 
be more reabsorption of water and sodium which leads to expansion of 
extracellular fluid content . This leads to hypertension in CKD patient . 
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Extracellular fluid expansion is isotonic as long as kidney capacity to 
excrete fluid and sodium is  normal .Once capacity decreased there will be 
hyponatremia  that is usually dilutional and will respond to water restriction 
. Diuretics may be needed to decrease volume overload . As renal function 
deteriorates further there will be more and more diuretics resistance 
requiring early initiation of dialysis  
Potassium homeostasis : 
       Potassium  homeostasis is deranged in CKD . It is not necessary that 
decrease in renal function causes increase in body potassium . It is because 
potassium excretion depends on aldosterone in distal nephron segments  and 
potassium excretion through Gastrointestinal tract increased in CKD 
patients  
Precipitating factors for hyperkalemia in CKD patients are  
 Increased dietary  potassium intake  
 Protein catabolism especially in fasting state  
 Hemolysis ,hemorrhage  
 Transfusion of stored red blood cells  
 Metabolic acidosis  
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Most important medication that causes increased potassium is ACE 
inhibitors , Angiotensin receptors blockers ,spiranolactones and other 
potassium sparing diuretics like amiloride ,triampterene  
Some forms of CKD are associated with early disruption of potassium 
homeostasis out of proportion to decrease  in GFR . In those category 
include mainly diabetic nephropathy , obstructive uropthy , sickle cell 
nephropathy . 
Hypokalemia not so common in CKD .Its presence indicates severe 
dietary potassium  lack , severe gastrointestinal potassium loss , excessive 
diuretic therapy  
Metabolic acidosis: 
              Its is very common in advanced CKD .These patients cannot 
excrete adequate quantities of protons .Hyperkalemia increases the 
incidence of metabolic acidosis  through decreased production of 
ammonium ions . Hyperkalemic , hyperchloremic metabolic acidosis is very 
common even in earlier stages of CKD . The latter finding is more common 
in patients with diabetic nephropathy and those with tubulointerstitial 
disease and obstructive uropathy  
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With decreasing renal function daily acid excretion decreases to less than 30 
to 40 mmol per day. Anion gap metabolic acidosis is caused by retained 
organic acids . In most patients metabolic acidosis is mild and pH  is rarely 
less than 7.35.It can be corrected with oral sodium bicarbonate 
supplementation . Alkali supplementation also slows down progression of 
CKD  and is routinely prescribed for patients when bicarbonate 
concentration is less than 20-23 mmol/lit 
Disorders of calcium and phosphate metabolism :  
             These occur in skeleton and vascular tissues Bony changes in CKD  
occur due to high bone turn over with increased parathormone level , and 
low bone turnover due to decreased paratharmone level  
In CKD there will be hyperparathyroidism due to  
 Retention of phosphate due to diseased kidney  
 Decreased level of ionized calcium  
These changes will start when GFR falls below 60ml/min  
Fibroblast growth factor -23 is an important phosphatonin that promote 
phosphate excretion .It is elevated early in CKD .It will be elevated early in 
CKD which will protect against development of hyperparathyroidism . 
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Hyperparathyroidism stimulates bone turnover and leads to osteitis fibrosa 
cystica . PTH is considered as important uremic toxin and high level of 
which is  associated with muscle weakness ,fibrosis of cardiac muscle , 
nonspecific symptoms   
Low turnover of bone lead to adynamic bone disease and osteomalacia  
which will lead to increased incidence of fractures and increased vascular 
and cardiac calcification .  
In CKD  patients calcification in media of coronary artery and in heart 
valves is of greater proportion compared to non CKD patients  
Calcific uremic arteriolopathy that is almost exclusively occurs in patients 
with CKD . Pathology involves vessel obstruction and enormous vessel wall 
and soft tissue calcium deposition . Previously it was associated with 
hyperparathyroidism . But recently it is found even in the absence of 
hyperparathyroidism .Warfarin used in dialysis is found to be risk factor for 
development of  calciphylaxis  
Cardiovascular abnormalities : 
Cardiovascular abnormalities are main causes of mobidity and mortality 
among patients with CKD. 
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Risk of cardiovascular diseases increases by 10 to 200 fold in CKD patients 
depending on stage of CKD . In stage 5 CKD almost all patients have some 
form of cardiovascular abnormality . So management of CKD in earlier 
stages should aim at preventing development and progression of 
cardiovascular complications. 
Important among cardiovascular diseases in CKD patients is ischemic 
vascular  disease  which include  
• Blockage of coronary arteries due to atheroma   
• Diseases of vessels supplying brain  
• Vessels of periphery   
In CKD there will be additional risk factors  that add to cardiovascular 
diseases like 
 Anemia  
 Hyperparathyroidism  
 Hyperphosphatemia  
 Sleep apnoea  
 Generalized inflammation  
This along with traditional risk factors like hypertension ,hypervolemia , 
dyslipidemia , sympathetic overactivity  lead to increased incidence of 
vascular diseases .In CKD there will be additional  increased circulating 
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acute phase reactants  like cytokines and C reactive protein with fall in 
albumin and fetuin  
This inflammatory state accelerates vascular occlusive disease and 
decreased fetuin causes rapid vascular calcification . 
In CKD there will be left ventricular hypertrophy and microvascular disease 
that leads to myocardial ischemia .These things causes myocardial 
infarction and congestive cardiac failure .  
Cardiac troponins are usually elevated in patients with CKD without 
evidence of myocardial  ischemia . This elevation causes confusion in 
diagnosing myocardial infarction unless serial measurements are done .       
Heart failure :       
In CKD there is abnormal cardiac hypertrophy  ,myocardial ischemia and 
cardiomyopathy  with salt and water retention that leads to  heart failure and 
pulmonary edema   
It may due to systolic or diastolic dysfuncfion .  
In  uremic state there is increased permeability of capillary membranes that 
lead to pulmonary edema even in the absence of increased pulmonary 
capillary pressure . 
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Hypertension and left ventricular hypertrophy  : 
             Hypertension is very common CKD. Presence of hypertension leads 
to rapid deterioration of kidney function, early left ventricular hypertrophy  
Presence of anemia and creation of arteriovenous fistula leads to high output 
failure . Chronic extracellular fluid overload also increases blood pressure. 
So diuretics , salt restriction ,dialysis to remove excess fluid will decrease 
blood pressure and leads to better cardiac functioning . 
Pericardial disease:      
Pericarditis is common in uremia which leads to chest pain. It may also 
associated with pericardial  effusion leading to cardiac tamponade. 
Pericarditis is observed in advanced uremia. More common in 
underdialyzed , nonadherent patients than in those starting dialysis .    
Hematological abnormality in CKD 6     : 
      Anemia is most common abnormality seen .It is most commonly 
normocytic , normochromic . It appears as early as in stage 3 and almost 
common at stage 4 & 5 . 
 Anemia in  CKD  caused by :  
• Decreased erythropoietin production  
• Diminished red blood cell survival  
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• Bleeding diathesis  
• Iron deficiency  
• Hyperparathyroidism and bone marrow fibrosis  
• Chronic inflammation  
• Folate and Vit B 12 deficiency  
• Hemoglobinopathy  
• Comorbid  conditions  
Abnormal hemostasis : 
                    Patients with CKD especially in terminal stages have increased 
tendency to bruising, bleeding from surgical sites ,menorrhagia and 
spontaneous bleeding. They have increased  bleeding time,reduced 
functioning  of platelet factor 3,  platelet aggregation defect, 
adhesiveness.and  defect in prothrombin utilization . CKD patients are more 
prone for thromboembolism especially those with nephrotic range 
proteinuria . 
Neuromuscular abnormality7: 
                           All three namely  central nervous system , peripheral 
nervous system, autonomic nervous system are involved in CKD  , as well 
as muscle . Nitrogenous waste products , middle molecules ,are responsible 
for this .   As early as stage 3 CKD neurological disease may appear . 
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 Neuromuscular  irritability , hiccups ,cramps ,fasciculations  or twitching 
may develop  
In advanced cases asterixis  , myoclonus ,seizures , coma may develop. 
Peripheral neuropathy develops at the stage of  4. 
Initially sensory more than motor , lower limb more than upper limb ,distal 
more than proximal involved .  
Restless leg syndrome is peculiar abnormality seen  in CKD patient . 
Presence of neuropathy in patients with CKD is an indication for renal 
replacement therapy 
Gastrointestinal abnormality8: 
               Uremic  fetor  is a urine like odour of breath . It occurs due to 
breakdown of urea to ammonia in saliva and associated with metallic taste. 
Other abnormalities like gastritis , peptic ulcer disease, mucosal ulceration 
may develop .Patient  may develop constipation that is aggravated by 
administration of iron and calcium supplementation. Decreased appetite, 
nausea and vomiting may develop . 
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Endocrine and metabolic disturbances9 : 
Glucose metabolism is impaired in patients with CKD .But fasting blood 
glucose will remain  normal in patients with CKD . 
Insulin is degraded by kidney .So in kidney dysfunction insulin level will be 
elevated .  
In women estrogen level is low .There may develop abnormalities related to 
menstruation and pregnancy .They may develop spontaneous miscarriage 
especially when GFR has dropped below 40ml/min . 
Men  with CKD have decreased testosterone levels . They may suffer from 
sexual dysfunction and decreased sperm count . 
Dermatological abnormality: 
Common with CKD especially in late stages.  
Pruritis is the most common condition in uremic state . 
Patients are hyperpigmented due to deposition of pigmented retained 
metabolites like urochrome . 
Nephrogenic fibrosing dermopathy ,is a condition in which there is 
progressive subcutaneous induration especially in arms and legs .It is most 
common in patients with CKD with exposure to Magnetic resonance 
scan(MRI )with gadolinium contrast .So in patient with CKD who undergo  
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MRI Scan with contrast it is recommended  to remove contrast material 
through hemodialysis . 
Diagnosis of CKD :  
Initial history and physical examination :  
 Signs and symptoms during initial stages are often minimal . When stage 
reaches 3 or 4 patient becomes symptomatic . Initial symptoms are mild and 
often subtle .When the patient comes to know that they are having CKD its 
often surprising .  History of hypertension , diabetes mellitus and chronic 
drug intake may point towards the cause of CKD . Chronic drug intake 
especially NSAIDS  other anti-inflammatory agents , gold penicillamine, 
antimicrobials , chemotherapeutic agents , antiretroviral agents ,proton 
pump inhibitors , lithium and other  drug history should be  investigated as a 
part of diagnostic questionare .  
Physical examination  should be done to find out target organ damage due to 
hypertension arising  from CKD . Fundus examination to find out 
retinopathy , cardiac examination to find out  left ventricular failure should 
be carried out  
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Laboratory evaluation  : 
Tests   should  focus on finding clues to the cause of CKD , aggravating 
factors , degree of renal damage and its consequences . Serum and urine 
protein electrophoresis  should  be obtained in all the patients who are above 
35 years of age to rule out multiple myeloma especially if there is anemia 
and increased serum calcium level in the face of renal insufficiency  
In  presence of glomerulonephritis autoimmune diseases such as lupus 
nephritis and  underlying etiologies such as hepatitis B and hepatitis C  and 
HIV should  be investigated . Serial measurements  of renal parameters like 
blood urea and serum creatinine to ensure that renal damage is chronic and 
not an acute deterioration  and reversible . Serum concentrations of calcium, 
phosphorus , vitamin D , and Parathormones should be measured  as a part 
of evaluation of metabolic bone disease . Hemoglobin concentration , iron , 
Vit B 12 and folate should be evaluated . 24 hour urine protein must be 
evaluated which will help to find out >300 mg protein excretion to suggest 
therapy with ACE inhibitors or ARBS . 
Imaging studies :  
          The most important and useful investigation is renal ultrasonography 
which will  help to find out  presence or absence of two kidneys,whether 
they are symmetric , size of both the kidneys, to rule out renal mass  or 
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evidence for renal obstruction . As CKD is a chronic process there will be 
contraction of kidney . Presence of bilaterally small kidneys support the 
diagnosis of CKD of long standing duration with an irreversible component 
of scarring .If the kidney size is normal  it indicates  that the process is acute 
or subacute . The exception to this are diabetic kidney disease which often 
show normal or increased kidney size  and amyloidosis  and HIV 
nephropathy where kidney sizes are normal in the pace of CKD . Polycystic 
kidney disease show often enlarged kidney with multiple cyst. A  
discrepancy of more than 1 cm in kidney length suggest either a unilateral 
developmental defect or a disease process or renovascular  disease with  
arterial insufficiency affecting one kidney more than other . Diagnosis of 
renovascular disease can  be done by Doppler ultrasonography, nuclear 
medicine studies , CT or  MRI .If there is suspicion of reflux nephropathy a 
voiding cystourethrogram should be done  
Renal biopsy  : 
          Usually done  under the guidance of ultrasongraphy is the favoured 
approach . Biopsy is not indicated in  bilateral small kidneys because  
1. If  it is technically  difficult to perform and risk of 
major bleeding and other adverse consequences 
2. There  is so much scarring that underlying disease  
may not be apparent  
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3. Window of opportunity for specific therapy has passed 
Other contraindication for renal biopsy are  
1. Uncontrolled hypertension   
2. Active urinary tract infection  
3. Bleeding diathesis  
4. Severe obesity  
A short run of hemodialysis  before renal biopsy may be useful to normalize 
bleeding time in those who have increased bleading time   
Establishing diagnosis of  chronicity of disease : 
         It is important to differentiate  between  acute kidney failure from 
chronic renal failure because acute renal failure is often reversible if 
appropriate measures are taken and needs only short time  management until 
kidneys recover its functions. If previous values are known , recent 
elevation points to more acute process  for renal dysfunction . In contrast if 
elevated serum concentration in the past suggests that renal disease 
represents a progression of chronic process .  Even if the disease is chronic 
an acute insult in the form of dehydration , or toxin exposure or sepsis might 
have precipitated a sudden worsening of kidney function  
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Some other parameters suggest a chronicity of desease . The  presence of 
metabolic bone disease  with hyperphosphatemia , hypocalcimia , elevated 
PTH and bone alkaline phoshatase suggests chronicity. Normocytic 
normochromic anemia suggest that the process is ongoing for long duration.  
The presence of bilateral reduced kidney size ( < 8.5 cm in all but the 
smallest adults ) suggest chronicity . 
Diagnosis of etiology of CKD  : 
Renal biopsy is may be helpful in diagnosis of CKD but it is not always 
necessary . If a patient is  suffering from diabetes  for long duration and he 
has nephrotic range proteinuria its very obvious that cause of CKD is 
diabetic nephropathy . It is also very clear that a person suffering from 
hypertension that ischemic nephropathy the cause of CKD . If diagnosis is 
not obvious renal biopsy may be undertaken  . 
Criteria for referral of chronic kidney disease patients to nephrologist  : 
 Age of patient < 40 years  
 Stage 4 CKD or worse  
 Rapid deterioration in renal function  
 Significant proteinuria  ( PCR > 100 mg /mmol  or ACR > 
70 mg /mmol  
 Significant  hematuria   
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Treatment of CKD :  
       Depends on stage of CKD  
STAGE EXPLANATION GFR ml/min per 1.73m2 Treatment 
1 
Kidney damage with 
normal or increased GFR  
>90 Diagnosis and 
treatment of 
comorbid condition, 
slowing the 
progression , 
cardiovascular risk 
reduction   
2 
Kidney damage  with mild  
decrease in GFR 
60-89 ESTIMATING 
PROGRESSION  
3 
Moderate  decrease in GFR 30-59 Evaluating and 
treating the 
complication  
4 Severe decrease in GFR 15-29 
Preparation for 
kidney replacement 
therapy 
5 Kidney failure 
< 15 or on 
dialysis 
Kidney replacement 
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Slowing  the progression of  the CKD : 
Reducing intraglomerular pressure and proteinuria : 
Control of systemic and glomerular hypertension are important in slowing 
down the progression of chronic kidney disease .So antihypertensive 
therapy aimed at reduction of intraglomerular pressure .Proteinuria is 
increased by systemic hypertension due to increased flux across glomerular 
capillaries. Antihypertensive medication decreases the proteinuria thereby 
decreases the decline in GFR further .So target blood pressure of 125/75 has 
been kept for CKD patient to reduce proteinuria and progression of CKD . 
ACE inhibitors and Angiotensin receptor blockers are found useful in 
progression of CKD . They cause decrease in intraglomerular pressure by 
inhibiting angiotensin induced constriction of efferent arterioles   
They are  also found to decrease proteinuria and progression of CKD . 
Calcium Channel blockers like verapamil and diltiazem are also found 
useful  
Slowing progression of diabetic renal disease: 
Blood glucose control:  
                      Tight glycemic control  decreases the chances of renal disease 
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Control of blood pressure and proteinuria  : 
Hypertension is seen in majority of patients with diabetes mellitus. This  
finding correlates with presence of albuminuria and it is one of the 
important predictors of cardiovascular events and nephropathy. 
Antihypertensive treatment reduces  the albumin excretion even in 
normotensive patients   
Patients should be planned for renal replacement therapy either in the form 
of dialysis or transplantation once end stage renal disease establishes . 
Dialysis in patients with chronic kidney disease may be may be 
indicated in   
1. Presence of uremic symptoms  such as uremic gastritis , uremic 
pericarditis  
2. Electrolyte disturbance such hyperkalemia unresponsive to 
conservative  therapy 
         3.Persistent extracellular volume expansion despite adequate diuretic 
therapy 
         4. acidosis refractory to medical therapy  
         5. bleeding diathesis  
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             6. creatinine clearance or estimated glomerular filtration rate below 
10 ml/min per 1.73 m2  
   In end stage renal disease the treatment options may be  
                                     Hemodialysis  
             Peritoneal dialysis as continuous ambulatory peritoneal dialysis or 
continuous cyclic peritoneal dialysis  
                                     Transplantation   
   Hemodialysis   : 
It relies on principle that of solute diffusion across a semipermeable 
membrane . Movement of metabolic waste products takes place down the 
concentration gradient  from the circulation into dialysate  .The rate of 
diffusive transport increases in response to several factors like magnitude of 
concentration gradient , membrane surface area  and the mass transfer 
coefficient of the membrane . According to law of diffusion , the greater the 
size of molecule slower its rate of transfer across the membrane . Smaller 
molecules like urea (60 Da  ) undergoes substantial clearance , but a larger 
molecules like creatinine( 113Da )  undergoes less clearance . In addition to 
diffusive clearance there take also place ultrafiltration of waste products  
from the circulation into the dialysate . 
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Complication of hemodialysis   : 
 1. Hypotension is the  most common acute complication of hemodialysis .  
Factors affecting development of hypotension are rate of ultrafiltration, 
impaired vasoactive or autonomic response , osmolar  shift ,excessive use of 
antihypertensive agents ,reduced cardiac reserve. 
Patient with arteriovenous fistula may develop high output cardiac failure 
through shunting of blood through dialysis access . Acetate used in dialysate 
because of its vasodilatory and cardiosuppressive effect may  aggravate 
hypotension . 
2.Muscle cramps are also common during dialysis .Etiology for this is 
obsure . Changes in muscle perfusion due to excessive aggressive volume 
removal and use of sodium containing dialysate may be the cause . 
3 .Anaphylactoid reaction commonly with  first time use especially with 
bioincompatible cellulose containing membrane . With use of cuprophane 
membrane this dialyser reaction has become less common . 
4. Progressive loss of remaining nephrons  is expected in patients on chronic 
hemodilaysis due to decreased work of remaining nephrons and atrophy 
5. Cardiac arrhythmias  
6. Air  embolism  
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Between treatment patients may develop pulmonary edema and systemic 
sepsis   
Peritoneal dialysis  : 
In peritoneal dialysis , 1.5 to 3 litres of dextrose containing solution is 
infused into peritoneal cavity and allowed to dwell for a set period of time  
around 2-4 hours .Toxic materials are removed through a combination of 
convective clearance  generated through ultrafiltration and diffuse clearance 
across a concentration gradient .The clearance of solutes and water  depends 
on movement of water and solutes into the peritoneal cavity  versus 
absorption from peritoneal cavity .Rate of diffusion diminishes  with the 
time as equilibrium is reached between plasma and dialysate .Rate of solute 
transport varies from person to person and  altered by factors such as  
peritonitis , drugs , physical factors like position of patient and exercise . 
Types of peritoneal dialysis : 
1. Continuous ambulatory peritoneal dialysis  
2.  Continuous cyclic peritoneal dialysis  
Complicatios of  peritoneal dialysis : 
Peritonitis is most common complication in patients with peritoneal dialysis. 
It can be suspected by drainage turbid dialyste or finding more than 100  
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leukocyte withmore than 50% polymorpholeukocytes. Staphylococcus is the 
most common organism indiacating travel of organism from skin due to 
breach in sterile  technique in access to peritoneal cavity . It is usually 
managed with intraperitoneal or intravenous antibiotics . 
Patients on peritoneal  dialysis are prone to number of metabolic 
complications . Due to high dextrose in dialysate patients are prone to 
hyperglycemia   especially patients with diabetes mellitus who develop 
insulin resistance . Due to loss of albumin in dialyate fluid patient develop 
hypoproteinemia and its complications .  
Sclerosing peritonitis may  develop due to infectin and inflammation . 
Transplantation : 
If HLA matched donors are available transplantion of kidney can be 
undertaken in patient with CKD in the ESRD .It may be an orthotopic or 
heterotopic kidney transplantation . Nowadays heterotopic kidney 
transplantation are performed frequently . 
Contraindication for renal transplantation are ; 
Absolute contraindication : 
Active malignancy ; A period of atleast two years of complete 
remission is recommended for most tumour  
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Active vasculitis or recent anti GBM  diseases  
Severe heart disease  
           Severe occlusive aorto -iliac vascular disease  
Relative contraindication : 
Age , transplantation not done routinely for child < 1 years or > 75 
years  
High risk of disease recurrence in transplanted kidney  
Diseases of the lower urinary tract  
Significant comorbidity  
                                             
Complication of transplantation : 
                Graft failure  
                 Drug toxicity due to use of immunosuppressents  
                 Graft versus host disease  
                 Opportunistic infection particularly with cytomegalovirus  
                 Hypercalcemia 
                Hypertension due to residual kidney diseases    
                Chronic hepatitis  
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Causes of death in CKD  : 
Cardiovascular disease constitutes major cause of death in patients 
with CKD . Cardiovascular events are more common in patients with 
hemodialysis than with  post transplantation patients.  Increased 
cardiovascular morbidity may be due to diabetes mellitus ,hypertension , 
atherosclerosis , dyslipidemia ,anemia , dystrophic vascular calcification , 
hyperhomocysteinemia .Patients are highly prone for myocardial infarction , 
cerebrovascular accidents . 
Other causes of death are severe anemia with heart failure . infections , 
dialysis related complications , comorbid condition which has caused the 
CKD    
Homocysteine :   
In  1932  Botz  and  Vizwand initially described homocysteine .But 
its link with human disease was described only later in 1962 
  Inborn errors of homocysteine leads to very high homocysteine level . 
Physician Dr McCully  demonstrated that early onset of atherosclerosis in 
patients with increased homocysteine even in children . He stated that even 
mild elevation of homocysteine can cause atherosclerosis 10.But people 
rejected his hypothesis 
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          Homocysteine formed during metabolism of methionine .It is a thiol 
containing   intermediate aminoacid.  Average plasma total homocysteine 
for an healthy human being is less than 15micromol/lit. . Allon Freidman 
describes in journal of kidney and homocysteine metabolism that in the era 
of fortification with folic acid the amount of normal homocysteine in plasma 
is 6 to 12micromol/lit . 
Mild  hyperhomocysteinemia at level of 12 to 30 micromol/lit 
Intermediate hyperhomocysteinemia at level of 31 to 100 micromol/lit 
Severe hyperhomocysteinemia as more than 100 micromol/lit 
In normal persons 75%  of total homocysteine are bound  through a 
disulphide bond to proteins mainly to albumin . 
Remaining 25% remains in the free form . Free form exists in almost 
oxidized form as disulphide linked heterodimers( homocysteine-cysteine) or 
as homodimers (homocysteine –homocysteine) 11.Free homocysteine is 
unstable and its level is difficult to measure .  Free homocysteine is  the only  
only one  which freely filters through kidney at glomerulus  . fHcy/bHcy  
fraction varies among different species .   
Homocysteine  is produced in all the cells due to normal methylation 
process . 
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Intracellular homocysteine level increases either because of increased 
homocysteine production or due to inhibition of intracellular metabolism  
Homocysteine is regularly  synthesized and exported out of cells there must 
be some mechanism to keep plasma level within normal limit .   
 
   Types of homocysteine 
 
Homocysteine is synthesized and metabolized   by three different process 11  
1. demethylation process  
2.   transmethylation process 
3. Transulfuration process 
 
Hcy is synthesized inside the body from essential aminoacid 
methionine and is not obtained from diet  
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Demethylation 
In this process methionine is converted into intermediate metabolites  like 
 S-adenosyl methionine and S-adenosyl homocysteine. 
Transmethylation 
 Remethylation  of  homocysteine  to methionine occurs in this process. 
By using Vit B 12 and 5- mehtyltetrahydrofolate as a substrate 
homocysteine is converted back into methionine . 
Betain  homocysteine methyl trasferase remethylates homocysteine to 
methionine in liver  and kidney mainly in an alternate reaction .   
Transsulfuration 
In this process,  cysteine formed from homocysteine in an irreversible 
reaction .  
Reaction  is catalysed by  cystathionine B-synthase , a  pyridoxal-5 
phosphate /Vit B6 dependent enzyme to form cystathionine. Cystathionine 
is hydrolysed to form cysteine ,ammonium and alpha ketoglutarate  
Folate or Vit B12 deficiencies causes increased homocysteine level by 
impairing homocysteine remethylation . Vit B6 deficiency causes defective 
transulfuration  and increased homocysteine level .  
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METABOLISM  OF  HOMOCYSTEINE 
 
Measurement and Classification of Homocysteine Levels 
The normal level of  plasma homocysteine is 5-15 µmoles/lit .Level in the 
plasma   greater than 15 µmoles/L is considered as hyperhomocysteinemia. 
Hyperhomocystenemia classified by American Heart Association into 12 
Moderate : homocysteine level  15-30 µmoles/L 
Intermediate : 30 - 100 µmoles/L 
Severe : >100 µmoles/L 
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Measurement  of plasma homocyestine: 
A  blood  sample, which preferably in  a fasting patient, is the most 
commonly  taken test  to assess homocysteine status. Careful handling of 
sample is most important to correct estimation of plasma homocysteine . 
Plasma should be measured for homocysteine early after collection or blood 
kept at 4 degree celcius . If not done like this homocysteine level increases 
due to hemolysis . 3-deaza-adenosine or fluoride can be used for prompt 
stabilization of plasma homocysteine  
Methods of estimation of plasma homocysteine 12 
1.  ELISA 
2 . High  performance liquid chromatography 
3 . Fluorescence polaraization immunoassay 
4 . Mass spectrometry 
Classification of hyperhomocystinemia  
 Hyperhomocysteinemia classified into 13 
1. Primary 
2. Secondary 
 
1. Primary hyperhomocysteinemia 
Due to defects in enzyme which are involved in homocysteine metabolism  
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a. Cystathionine beta synthase (CBS) deficiency: 
The  most frequent cause of hyperhomocystinemia due to genetic deficiency 
of enzyme involved in homocysteine metabolism . It is autosomal recessive 
disease . 
It is characterized by premature atherosclerosis , dislocation of lens , 
skeletal abnormalities, mental retardation , homocystinuria..Affected 
persons will be having homocysteine level between 20-40umol/litre.Its 
incidence is around 1in  3 lakh  
b.  5,10 methylene tetrahydrofolate reductase (MTHFR) deficiency 
A mutation invoving  the enzyme MTHFR is associated with 
hyperhomocysteinemia in persons with low folate level  
c. Methylene tetrahydrofolate homocysteine methyl transferase 
deficiency14 
2. Secondary hyperhomocysteinemia: 
a. Physiological 
                                     - Male sex                        
                                     - Increasing age 
                                     - Menopause 
b. Lifestyle factors – 
                               - Excessive Coffee consumption                                 
                               -  Tobacco use 
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c. Vitamin deficiency – 
                                Vit B12  (cobalamine)  ,Folic acid,  Pyridoxine ( Vit B6) 
d. Systemic disorders 
(i)  Severe hepatic impairment  
(ii) Pernicious anemia 
(iii) Psoriasis 
(iv) Renal impairment 
(v) Systemic lupus erythematosus) 
(vi )  Hypothyroidism 
(vii)  Organ transplantation     
 (viii) Anorexia nervosa 
(ix) Malignancies of breast and ovary 
e. Drugs 
1)) Folate antagonists – Carbamazepine, Phenytoin 
2) cholestyramine ,colestipol ,metformin (affect folate and cobalamin  
    absorption 
3) L-dopa  
4)  Vit B6 antagonists (theophylline, oestrogen containing OCP ,niacin) 
5) Androgens 
6)  Nitrous oxide (inactivates methionine synthesis) 
7)  cyclosporins , fibric acid derivatives ( Causes renal dysfunction ) 
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Determinants of plasma homocysteine level15 : 
Variable  Fasting plasma 
homocyteine level 
Sex Male 10.3 
 Female 8.8 
Age(years)   
 <45 8.8 
 45-54 9.2 
 54-64 9.8 
 >65 10.4 
Serum creatinine(mol/lit)   
 <79 8.7 
 79-87 9.3 
 87-96 9.3 
 96-106 9.7 
 >106 10.5 
Alcohol intake(g/d)   
 0.1-4.9 9.3 
 5.1-4.9 9.4 
 >15 10.0 
Caffeine intake(mg/d)   
 <88 8.9 
 >420 9.9 
Current cigarette smokers   
 0 9.3 
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 1-15 9.9 
 16-25 10.1 
 >26 11 
Body mass index(kg/m2)   
 <23.2 9.4 
 >30.6 9.9 
 
Main determining factors of plasma homocysteine are vit B12 ,folic acid , 
vit B6 which are present in the food  . A 0.5 to 5 mg of folic acid daily 
reduces the plasma homocysteine level by 25% . Adding vitamin B12 to 
folate further reduces the homocysteine levl by around 7% 16. 
Functioning of kidney is an important determining factor of maintenance of 
normal homocysteine level because of its intrarenal  homocysteine 
metabolism and excretion of homocysteine . 
Coffee intake and smoking showed positive association with homocystiene. 
Moderate alcohol lowers while chronic alcoholics have increased plasma 
homocysteine  level. 
 
Effects of Homocysteine: 
Homocysteine produces atherosclerosis, favours intravascular thrombus 
formation and subsequent embolisation   and damage to the vascular 
endothelium . It affects endothelial surface, plasma lipoproteins , vascular 
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smooth muscle cells , platelets, coagulation factors, blood lipids and 
connective tissues. 
Homocysteine stimulates& increases DNA synthesis, cyclin activity, 
vascular smooth muscule proliferation . It causes decrease in activity  of  
NA+ - K+ - ATPase  and  causes hemolysis of  red blood cells .and increases  
platelet adhesion and aggregation 
Homocysteine may facilitate increased binding of fibrin and lipoprotein (a). 
In high concentration it causes factor 5 activation , protein C inactivation, 
cofactor activity of thrombomodulin  inactivation , suppression  of  
thrombomodulin. 
Hyperhomocysteinemia and atherosclerosis17: 
Homocysteine preidisposes to atherosclerosis and thrombosis by causing 18 
1. Endothelial injury  
2. Platelet activation  
3. Smooth muscle proliferation  
4. Oxidative modification of low density lipoprotein  
5. Endothelial – leukocyte interaction  
Endothelial injury : 
Endothelium is a comprising vascular inner layer will maintain 
hemostasis in vessesls and support proper blood and oxygen supply to the 
tissues . 
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According to  response to injury hypothesis   the  primary event in the 
atherosclerosis  is damage to the endothelium  and malfunctioning of  which 
halts many normal  characters of endothelium  resulting in leukocytes and 
platelet adhesion ,thrombus formation proliferation of smooth muscles , 
spasm of vessel ,lipid collection ,and finally atherosclerosis   
Homocysteine  concentration between 1-10 umol/lit was found to 
cause damage to   vascular endothelial cells depending on dosage  in human 
umbilical vein . Hydrogen peroxide generated by the copper catalysed  
autooxidation of homocysteine in which copper acts as catalyst was thought 
to cause vascular endothelial damage  by the demonstration of reduction in 
toxicity by addition of catalse . There was high strand  breakage and 
decreased level of nicotinamide adenine deaminase level in endothelial cells 
which have been incubated in high concentration of homocysteine   .This 
shows homocysteine causes induction of DNA breakage  ,also prevents  
DNA production in human umbilical vein endothelial cell in a manner 
which depends on  concentration of homocysteine  . These effects on DNA 
causes not only damage to endothelial cells also impairs ability to regenerate 
following injury and decreased synthesis of enzymes involved in 
transmethylation and transulfuration . This shows attack on DNA is an 
important mechanism of injury on endothelial cells by mediated by 
homocysteine  
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Endothelial dysfunction :  
Mechanism of endothelial dysfunction may be due to decreased nitric oxide 
or other mechanisms . Role of those substances involved and mechanism 
causing endothelial dysfunction  are narrated below.  
 
1.Nitric oxide : 
Nitric oxide  , endothelial derived regulates vascular tone ,prevents platelet 
activation ,adhesion ,aggregation ,limits smooth muscle proliferation ,and 
modulates leukocyte and endothelial interaction . 
Homocysteine  forms  S- nitrosohomocysteine by reacting with nitric oxide , 
which acts in a similar way  to nitric oxide .It causes vasodilation ,inhibits 
platelets aggregation .This is one of the protective mechanism against 
homocysteine mediated injury . It has been demonstrated  that patient under 
oxidant  stress shows that there is impairement of vascular nitric oxide 
activity by homocysteine . 
Studies  conducted both inside and outside the body shows that  
homocysteine causes decreased synthesis of nitric oxide by endothelial cells 
and they cause breakdown of nitric oxide structure by oxidizing it ,there by  
homocysteine decreases nitric oxide bioavailability . This is one of the most 
important and powerful mechanism by which homocysteine in increased 
concentration facilitates atherosclerosis and thrombus formation . 
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2. Gluthathione peroxidase:   
Hydrogen peroxide and peroxides of lipid are reduced to respective  
alcohols by Glutathione peroxidase , a substance  derived from endothelial 
cells  and  it protects against oxidant stress induced  damage to cells 
.Activity of glutathione peroxidase was found lower in 
hyperhomocysteinemia .There was a similar  reduction in glutathione 
peroxidase  mRNA levels in those patients . Homocysteine causes inhibition 
of glutathione peroxidase activity in vitro . It is the only one among thiols 
which decreses the  glutathione peroxidase activity .It is also helping to 
explain its greater toxicity by generating free radicals . 
 Disturbance of blood hemostasis : 
  Thrombosis is prevented on the vascular endothelial surface due to 
presence  of surface glycosaminoglycan- antithrombin III and 
thrombomodulin –protein C anticoagulation pathway, synthesis of 
plasminogen activators and inhibition of platelet activators , clotting factors  
which  are synthesized by endothelium  balances between  propensity 
towards clot formation and  and  in maintaining liquidity of blood there by 
helping to either thrombus formation or  preventing thrombosis under 
appropriate condition .   
This disturbance in  hemostasis caused by hyperhomocysteinemia  may be 
by  
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1.Stimulation of procoagulant factors ;  
In  bovine studies it has been shown that after treatment with homocysteine 
bovine endothelial cells exhibit more factor V activity.  Mechanism of 
action is induction of proteases endothelial cell activator of factor V  and 
gives an explanation  for thrombosis by homocysteine in the absence of 
thrombin . 
2.Prevention  of anticoagulation  mechanisms:  
 Endothelial cell of pigs  incubated in homocysteine have shown reduced 
expression of  heparin like glycosaminoglyacans . Hyperhomocysteinemia 
patients also exhibit decreased  functional  antithrombin III, as shown in 
small number of patients  .Bovine endothelial study has shown competitive 
inhibition of thrombin   to thrombomodulin activation  by homocysteine . 
Some research activists also telling that that homocysteine is responsible for 
inactivation of  both thrombomodulin  and  prorein C either directly or 
indirectly . Thrombomodulin expression  on the cell surface decreased by 
homocyteine   by  disturbing  the transit along the secretory pathway . 
Deliberate infusion of diet containing  excessive  homocysteine  in monkeys 
have caused  thoracic aorta  to contain 35% lower thrombomodulin 
dependent protein C  compared to normal diet infusion monkeys.  
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3. Fibrinolysis  impairement : 
        Endothelial cells  incubated with homocysteine was found to show less 
amount of  both tissue plasminogen activator activity and membrane 
binding sites . Lipoprotein (a) ,a atherogenic lipoprotein  reduces the 
fibrinolysis . Homocysteine  facilitates  lipoprotein (a) attachment  to fibrin 
thereby decreasing  the activation of plasminogen . 
4.Alteration  of platelet and endothelial interaction  : 
      Activation of platelets causes thrombus formation within the vascular 
compartment  and  proliferation of smooth muscles . So it plays an 
important role in atherothrombosis. EctoADPases are susbstances which 
break down ADP and hence prevents platelets activation and aggregation . 
Homocysteine in high concentration prevent this ADPases and hence 
facilitates platelet activation and aggregation. Prolonged exposure of 
endothelial cell  to homocysteine causes  prevention  of platelet aggregation 
which was originally  causesd  by nitric oxide . Studies have shown that 
acute elevation of  homocysteine  found to promote platelet aggregation and 
which  was prevented by co-administration of antioxidant vitamins like 
vitamin E and  C . It suggest that  stress caused by oxidative forces  can alter 
functioning of platelets  . 
  
 
 
                                                 
55 
 
Effects  directly on platelets  : 
         Increased homocysteine concentration causes increased release of  
vasogenic and thrombogenic agent called  thromboxane  , from  plasma 
which are highly concentrated with platelets  .  
Mcdonald et al, demonstrated exaggerated adhesion of platelets in patients 
with homocysteinuria  ,but there  is no experimental evidence to show  such 
kind of influence of homocysteine  on  platelet adhesion and aggregation . 
 Proliferation of vessel wall smooth muscle  : 
Proliferation of vessel wall smooth muscle  is an important aspect of 
atherogenesis. This process is stimulated  either by homocysteine  directly 
or because of  growth promoting  effect of growth factors released by 
endothelial cells and  platelets, which are released due to endothelial and 
platelet damage caused by excessive homocysteine   .Homocysteine also 
found to cause decrease in deoxy nucleotide  adenosine  (DNA)  production  
in  endothelial cells of umbilical veins  .As a whole  homocysteine  causes 
less damage  to the  smooth muscle cells than to endothelial cells . This 
appears to contribute to the mechanism in development of atheroma 
formation . 
Oxidative proliferation of low density lipoprotein : 
      Modified low density lipoprotein due to oxidation are found to have an 
vital  role in development of cholesterol induced atheroma formation and 
thickening of vessels  .Products of lipid peroxidation   which was indicated 
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by amount of one such product called thiobarbuturic acid was increased 
upon  incubation with homocysteine in umbilical vein endothelial cells . At 
present there is only some  proof  to show that  at high concentration of 
homocysteine increases the modification of low density lipoprotein due to 
oxidation  . 
Interaction between leukocytes and endothelial cell : 
 Adherence  of  white blood cells to endothelial cells is an vital  process in 
atherogenesis .  Human umbilical vein endothelial cells pretreated with 
homocysteine showed increased adhesion and transendothelial migration of 
neutrophils . Mechanism of increased interaction was supposed to be due to 
neutrophilic docking protein complex CD 11b /CD 18 and endothelial 
expression of monocyte chemoattractant protein -1 .  
Complications of hyperhomocystinemia 
1. Cerebrovascular disease  
2. Ischemic heart disease 
     3. Hypertension 
     4. Peripheral vascular disease 
    5. Venous thromboembolism 
 
 
 
 
                                                 
57 
 
Association between  hyperhomocysteinemia, peripheral vascular 
disease and stroke. 
Homocysteine  level  is increased in patients with  cerebrovascular accident  
and diseases affecting  vessels of periphery . As concerned with 
cerebrovascular disease, 11 clinical studies aimed  at  association  between 
homocysteine levels and cerebrovascular disease. In nine studies, there was 
significant relationship while two prospective studies lacked evidence for an 
association. Clark et al, reported that measurement of homocysteine after 
methionine loading  and subsequent measurement of homocysteine in men 
with early vascular disease  before ageing  revealed that 
hyperhomocysteinemia was observed in 28% of patients with peripheral 
vascular disease and 30% of coronary artery disease . 42% of patients 
suffering from diseases of vessels of brain 19 
Hyperhomocysteinemia and  thrombosis of veins : 
Increased   homocysteine is an  important independent risk factor for 
thrombosis  of venous system and subsequent embolisation  . 
Martin Den Haijer et al.20  reported that plasma homocysteine concentration  
in plasma  of  patients with history of repeated thrombosis of venous system 
was very high both in fasting state as well as after loading the patients with 
precussor substances like methionine as in the form of methionine loading 
test . The combination of increased homocysteine concentration  and  
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mutated  factor V further increased the relatve risk of venous 
thromboembolism upto 3.64 times . 
Homocysteine and diabetes mellitus21 
 Elevated  homocysteine levels were found in patients with type 2 diabetes 
mellitus who had macrovascular disease . 
 Hoogeveen et al. have demonstrated  if we compare subjects with normal / 
impaired glucose tolerance hyperhomocysteinemia is a stronger risk factor 
for cardiovascular diseases in type 2 diabetes mellitus (1.6  fold )  
Lakshman et al,  reported that higher levels of homocysteine was found in 
patients with diabetic nephropathy (  with microalbuminurea) , early type 1 
diabetes mellitus ,patients with autonomic neuropathy and patients with 
long standing diabetes with poor glycemic control . They also reported that 
higher serum concentration of homocysteine found in hypertensive type 2 
diabetes mellitus and diabetes with microalbuminurea  but it was not 
statistically significant . They found significant association with 
homocysteine and diabetic retinopathy  They reported a positive correlation 
between H bA1c and serum triglyceride  with homocysteine levels in both 
the diabetic groups . They conclude by telling that higher homocysteine was 
found  in diabetes patient with both microvascular and macrovscular 
complication  and it was highly correlated with HbA1c and serum 
triglyceride levels which are indicators of poor diabetic control .They say 
that hyperhomocystenemia could serve as a another parameter indicating of 
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poor diabetic control and development of complication .So homocysteine 
level in diabetes needs to be monitored  and if found elevated appropriate 
therapy to decrease is needed .   
  
Homocysteine and hypertension22 
Bortolotto LA et al  have shown  that hypertensive patients with high levels 
of homocysteine are associated with increased arterial stiffness. 
Kim Sutton et al, in their article showed  that homocysteine is independently  
and strongly associated with isolated systolic hypertension (ISH).According 
to them elevated blood pressure in older individual may be a cause of 
isolated systolic hypertension . Stiffening of central arteries may be the 
cause for ISH. Mechanism that is causing arterial stiffening are many . 
There are evidences which show increased homocyteine causes impaired 
nitric oxide mediated relaxation of vessel wall and increased smooth muscle 
cell proliferation . Other interesting mechanism may be stimulation of 
elastinolytic process in the arterial wall thereby causing increased stiffness 
of arterial wall  . 
Homocysteine and renal disease 
Kidneys play a vital  role in homocysteine metabolism. Patients with 
Failing  kidney , terminal kidney disease and  high concentration of urea in 
blood  have  increased concentration of homocysteine  and are  having more 
propensity towards  development  atherosclerosis. 
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Homocysteine and diseases of vessels of heart 23 
 Seventeen studies were evaluated were conducted regarding homocysteine 
and cardiovascular disease , out of which in 14 studies, homocysteine was 
found to be a significant risk factor  premature atherosclerosis and  
thrombus formation . It was 
calculated that 10% of all Coronary heart disease( CAD )risk in population 
was due to elevated homocysteine. 
It was observed that  a 30-40% reduction in risk of CAD by  long term 
lowering of homocysteine level by 3-4 umol/lit 
Study done by Boushey et al.24 based on meta analysis of 27 studies  shown  
that an  increased risk of Coronary heart disease ,peripheral vascular disease 
and venous thrombosis and embolism  with an  increase  in homocysteine 
concentration   15 µmol/L or greater  
Arnesen et al,25 showed  a significantly positive correlation between 
coronary artery disease  and homocysteine. In their case control study of 
21,656 subjects (11-61 years old), 123 developed  ischemic heart disease  
within a mean follow up period of four years. Homocysteine levels in cases 
were found to be significantly higher than that in controls. Thus, 
homocysteine can be attributed as independent risk factor. 
Nygard et26 al studied 587 angiographically documented cases. They 
reported  a 
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  association  between raised homocysteine and mortality  in manner that 
depends on concentration of homocsteine . According to them as 
homocysteine concentration increases severity of diseases increases .  
Chacko studied patients with CAD in Asian Indians and 53 control subjects. 
They concluded that homocysteine is not a major risk factor for coronary 
heart disease in Asian Indians.27 
Chambers et al28. studied UK Indian Asians with CAD and compared them 
with Europeans having CAD. They studied 764 male patients (257 Indian 
Asian and 507 European). Their results revealed that plasma homocysteine 
concentrations were  higher in Indian Asians compared with Europeans.  
Ford et al,29 analyzed the prospective trails and concluded that there was 
20% increase in cardiovascular risk for every 5 µmol/L increase in 
homocysteine levels  Enas A Enas et 30 al found that women with 
homocysteine levels more than 15.6 µmol/L had twice the risk of 
Myocardial infarction than the women with homocysteine levels 
<10µmol/L. 
 
 Stampher et al,31 In Physicians health study studied 14,916 male physicians 
without known atherosclerosis. Men are susceptible to myocardial infarction 
three times more compared to normal people when their plasma 
concentration increases 12% more than normal level .  
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Homocysteine and coronary artery  disease in young adults 
Myocardial infarction is claiming a large number of lives in young patients. 
Various studies have shown that homocysteine may be significant marker of 
risk in young patients lacking conventional risk factors . 
In a case control study by ogawa et al, 32  127 men with early myocardial 
infarction (<45 years) and 150 age matched controls and concluded that 
hyperhomocysteinemia is an independent risk factor for myocardial 
infarction.  
Khare A et al.33 studied homocysteine levels in 120 patients with myocardial 
infarction less than 40 years age. They concluded that elevated 
homocysteine levels were independently associated with CAD.  
VK Katyal et al.34, studied 100 young patients(less than 40 years) admitted 
with acute MI and found hyperhomocysteinemia to be a significant 
contributor towards premature CAD.  
Study conducted by Puri A et al35. involving 51 patients less than 45 years 
of age with CAD plasma homocysteine emerged as a significant 
independent risk factor for young CAD patients.51 
Stephen M Schwartz et al36 studied 79 women of age < 45 years diagnosed 
with MI and concluded that elevated plasma homocysteine and low plasma 
folate are risk factors for MI among young women. 
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Homocysteine  and pregnancy 37 : 
Studies are limited .Sunita Ghike et al,  in their study show  patient with  
severe pre eclampsia are found to have increased serum homocysteine value 
and severity correlate with increased homocysteine level . Foetal 
complications are more in patients with increased homocysteine in mother 
in the study group compared to normal control.  
Other studies points towards  elevated homocysteine level  in pregnant 
women was associated  increased miscarriage and fetal  congenital 
malformations . They also emphasize on supplementation  of vitamin B12 
and folic acid in preventing fetal malformation . Exact correlation between 
hyperhomocysteinemai in pregnancy and its effects needs further study . 
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TREATMENT 
  For reducing plasma level of homocysteine  the very successful, efficient 
and easy way is administering the patients with vitamin supplements like 
folic acid , vit B12 , and vitamin B6 . A strong negative correlation between 
folic acid level in the body and the plasma homocysteine levels has been  
reported. 
The guidelines of the American heart association advocate the principle of 
screen and treat, i.e., screening for hyperhomocysteinemia is recommended 
only in high risk population (personal or family history of premature 
atherosclerosis,myocardial infarction, hypertension, diabetes). 
It is recommended 38to keep the homocysteine levels to <10µmol/L in the 
high risk group. Those with hyperhomocysteinemia should be treated with 
dietary modification followed by vitamin supplementation or fortification of 
food with vitamins (400 µgm of folic acid, 2mg of vitamin B6 and 6µgm of 
vitamin B12).  
In  a trial aimed at stroke prevention by vitamin supplementation 39, patients 
with stroke and higher homocysteine levels were randomly allotted into two 
category , one category received heavy dose of vitamin supplementation and 
other category received low dose of vitamin supplementation  . There was 
reduction in the homocysteine level 2umol/litre more in the heavy dose 
receivers compared to low dose receivers . But there was no significant 
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differences in the reduction of  cerebrovascular events , coronary diseases 
and mortality after following the patients for two years . 
Results have shown that folic acid supplementation reduced plasma 
homocysteine by 41%, whereas Vit B12 supplement lowered homocysteine 
level by 14.8% and both were significant. The daily vitamin B6 did not 
significantly reduce plasma homocysteine level. The combination of three 
vitamins reduced plasma homocysteine by 49.8%. 39, 
 
Chronic kidney disease and homocysteine : 
     Normal  handling of homocysteine by kidneys 40,41 : 
                           It is now known that kidney play  a vital role in metabolism 
of  aminoacid.  Unbound aminoacids are filtered at glomerulus freely . 
Those filtered   level indicates the serum aminoacid level and glomerular 
filtration rate .Around 450mmol of aminoacids are filtered daily. More than 
90% are reabsorbed in proximal convoluted tubule and only around 5mmol 
per day excreted in urine . 
Tubular  cell  basolateral surface plays a minor role in uptake of aminoacid 
which mainly occurs in distal tubule cell .Homocysteine is probably taken 
up by this mechanism .  
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Homocysteine metabolism in kidney 42: 
 As with other aminoacids kidney plays a role in metabolism of 
homocysteine. Homocysteine has a molecular weight of 135 D  which  
comes  into the   filtration limit  of  renals . 
Assuming plasma free homocysteine  level  3 umol and normal  glomerular 
filtration rate  of  125 ml/min  daily amount of homocysteine filtered will be 
around 0.5 mmol .43 
As with other amino acid homocysteine is freely filtered at glomerulus , 
reabsorbed   at the tubules and minimally excreted .  
Specific mechanisms for reabsorption of homocysteine at tubular level have 
been recognized  . Studies in mouse models   have been found to have 
different channels for absorption including low km/high affinity ,high 
km/low affinity homocysteine uptake system . Low km/high affinity system 
shares process with cysteine and othe dibasic aminoacids like 
arginine,ornithine , lysine 43,44. 
Humans and rats45 show increased excretion of urinary homocysteine after 
bolus injection of aminoacid  arginine and lysine or alpha aminoisobutyric 
acid an inhibitor of lysine ,ornithine and arginine tubular reabsorption . 
Enzymes required for transulfuration  ( Cystathionine B synthase and 
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cystathionase ) and remethylation ( Methionine synthase )  in human 
predominantly found in kidney and liver . 
Some hypothesis says that kidney will alter its function so as to adjust for 
changes in  GFR by increasing  or decreasing  these two above said 
biochemical pathways  . According to this theory an elevation  in glomerular 
filtration rate  will  cause an  elevated  homocysteine filtration and tubular 
absorption 46.According to it increase in GFR will cause an upregulation  
homocysteine metabolizing enzymes. On the opposite hand if GFR 
decreases intrarenal homocysteine metabolism will fall . These adoptive  
mechanisms  make sure that alteration in homocysteine ultrfiltration do not 
affect renal homocysteine transportation to plasma47 . Healthy kidney has 
the capacity to filter, reabsorb,and  metabolise homocysteine In addition to 
filtered load homocysteine uptake also occur  on the basolateral tubular cell 
surface .   
Arteriovenous studies48 have been performed on normal human rat kidney to 
know the capacity of an organ to extract the homocysteine . Homocysteine 
concentration on the aterial side and venous side are measured after 
considering of kidney flow of plasma and loss of  the homocysteine  in the 
urine . These studies have shown that kidneys are capacitant enough of 
extracting homocysteine in very high  amounts . Limitation in this study was 
this did not take into account of the homocysteine produced by kidney. 
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Food intake and its effect on homocysteine filtration49: 
          Studies conducted on this have shown that dietary intake affects 
homocysteine  binding ,and  thereby homocysteine  fitration at glomerulus 
.One published data shows that there is significant increase in homocysteine 
level after a protein rich meal  with a peak level at 8 hour . Free 
homocysteine level increase was more significant than bound homocysteine 
.These experiments help to explain increase or decrease in homocysteine 
level based on dietary habits50 . Food containing high amount of protein like 
methionine  will lead to increase in plasma homocysteine level and cysteine 
level .Competition for protein binding and disulfide exchange reactions 
cause a disproportionate increase  in free homocysteine level .This causes 
excess free homocysteine to be delivered to kidney for filtration . Increase in 
free homocysteine also enhance uptake by tissues other than kidney . Both 
mechanisms including excessive filtration of homocysteine at the kidney 
level and upregulation of  homocysteine degradation pathway  in the kidney 
will lead to increased removal of homocysteine from the plasma . 
Recent data using  N-acetyl cysteine  (NAC) in acetaminophen overdose 
shows51 some interesting finding regarding protein binding and metabolism 
of homocysteine. 
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 N -acetyl cysteine  interacts with sulfhydril containing substances, also 
interacts with cysteine and homocysteine  displacing from other protein 
binding sites and forming mixed disulfides . Human subjects treated with 
NAC either oral form or intravenous form  shows significant often dramatic 
and dose dependent fall in homocysteine  and cysteine level  . NAC 
administration also  increases the free versus bound homocysteine . These 
findings show that alteration in binding of homocysteine to protein  of  
homocysteine protein binding  by drugs or or diet can temporarily  cause 
elevation  of  free homocysteine level thereby increasing glomerular 
filtration  and renal metabolism  
Diseased kidney and homocysteine handling52 :   
Correlation between GFR and homocysteine levels : 
                       Studies conducted till now  based on presumption that normal 
kidneys plays important and efficient role in homocysteine handling , 
homocysteine level increases as renal function deteriorates, reaching 
maximum level in the end stage renal disease( ESRD) , with majority of 
CKD patient in ESRD on dialysis having significant elevation of 
homocysteine values . 
Glomerular  filtration values calculated from serum creatinine or calculated 
creatinine clearance show inverse relationship with homocysteine values .It 
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is not sure however whether creatinine inversely predicts homocysteine 
levels  because it is a marker  of  GFR or simply because it is linked to 
homocysteine  production via a common  biochemical pathway. Many 
studies have been conducted using highly accurate GFR measurement in 
healthy and diabetic patient . These studies showed strong inverse 
relationship between homocysteine levels and renal function . This has been 
proved even with creatinine and more sensitive markers like cystatin C . In 
conclusion  homocysteine and renal function having an inverse relationship . 
It has been noted 53  using multiple markers of  GFR markers over a broad 
spectrum  of renal function  from severe kidney dysfunction  to a stage  very 
high above the the uremic range.This  indicates that increased homocysteine 
level in kidney diseases are highly linked with function of renal system  . 
Binding to plasma protein in kidney disease54   : 
  Free homocysteine , bound homocysteine and total homocysteine levels 
are  elevated in kidney disease  even though proportion of  free 
homocysteine remains constant  or decreases .In CKD patients in uremic 
patients who are frequently hypoalbumenic  have homocysteine bound to 
protein more compared to free homocysteine. It is hypothesized that 
retained uremic plasma proteins play a major role in binding homocysteine 
thereby increasing proportion of bound homocysteine concentration .Further 
studies are going on to find out proportion of free homocysteine, amount of 
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toxins in uremia and its effect on homocysteine binding  and potential 
toxicities of reduced homocysteine, free homocysteine, bound homocysteine 
in uremic environment 
Metabolism of aminoacids in Chronic kidney disease55 :    
Aminoacid handling ,metabolism and elimination are significantly altered in 
uremic environment .It may be because of uremia induced malnutrition or 
because of retained toxins, hormonal level derangement ,may be because of 
increased urinary amino acid excretion or may be because of  changing 
capacity of kidney to clear ,synthesize  and degrading certain aminoacids . 
Due to reduction in plasma level of certain essential aminoacid  like 
isoleucine , leucine valine , lysine and increases in levels of citrulline , 
cystine ,histidine ,glycine ,hydroxyproline and total non essential aminoacid  
there will be alteration in synthesis and amount products from these 
precussors .In normal persons excretion of total aminoacid is minimal it 
increases with progressive decline in renal function. This is due to higher 
plasma concentration of some specific aminoacid leading to increase in 
filtered load and and subsequent filtrate flow rate in few remaining 
functioning nephrons .This leads to decreased transit time and contact time 
between amino acid and tubule cells leading  decreased metabolism of these 
aminoacids and  and their increased excretion in urine . 
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Renal and extra renal metabolism of homocystine in Chronic kidney 
disease: 
Hyperhomocysteinemia in chronic kidney disease is due to defective 
clearance of homocysteine from decreased functioning of kidney . It is not 
due to increased delivery of plasma homocysteine .Kinetics studies56 were 
performed using oral and intravenous load of homocysteiney disease patient  
in chronic kidne showed  that clearance of homocysteine reduced in these 
patients compared to normal healthy subjects and subjects with Vit B 12 and 
folate deficiencies .This study shows that increase in homocysteine levels in 
these CKD patients are due to decreased clearance from malfunctioning 
kidney and decreased extrarenal metabolism caused by retained uremic 
solutes . At present there is no clear cut additional data to indicate that what 
level of defective metabolism is responsible for increase in plasma 
homocysteine level in CKD patients . Existence of homocysteine 
metabolizing  enzymes and other  aminoacid metabolizing enzymes have 
been identified in renal tubular epithelial cells . Homocysteine extraction 
studies in animals have proven significant uptake of homocysteine by 
tubular epithelial cells . With this studies it appears that loss of functional 
renal mass leads to decreased renal excretion of homocysteine and their 
level  increase in plasma . There appears inverse relationship between renal 
GFR and plasma homocysteine level as proven by many studies . 
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An alternate theory57 in chronic kidney disease and plasma homocysteine 
elevation is accumulation of uremic toxins and decreased extrarenal 
metabolism of homocysteine . The exact substances till now not identified , 
Liver appears the major target organ as it is involved in metabolism of 
majority of aminoacids in body . Liver additionally has got high level of 
homocysteine metabolizing enzymes so it plays major role in extrarenal 
homocysteine metabolism . In vitro studies have shown defective transport 
of folic acid in uremic mileu. Further studies in CKD paients showed no 
defect in absorption ,transport and conjugation of homocysteine . In another 
study  in rat it showed abnormal metabolism of sulphur containing 
aminoacid in uremic mileu 
Van Guldener et al 58, literature on homocysteine metabolism in chronic 
renal failure states that there are two options available to explain increased 
homocysteine levels in kidney failure patients   .One is defective clearance 
or metabolism by kidney itself .Another mechanism is systemic 
impairement of whole body homocysteine metabolism . .In that article they 
state that urinary homocysteine excretion in human is minimal , defective 
excretion itself cannot explain hyperhomocysteinemia in CKD patients . 
According to them loss of intratubular metabolism of homocysteine is main 
factor contributing to hyperhomocysteinemia in CKD  patients. 
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  Systemic factors may contribute59 to hyperhomocysteinemia in CKD  
patients . Including among those are deficiencies of vitamins like folate , vit 
B12 , vit B6 , genetic factors and altered total body homocysteine turnover . 
Role of vitamins can be studied by measuring plasma vitamin levels and 
measuring the homocysteine level after vitamin supplementation . But in 
CKD patients it was found that levels of vitamins are within normal range , 
but apparently insufficient to prevent hyperhomocysteinemia .But relation 
between vitamin level and homocysteine are maintained but at higher level 
than with the patients of normal renal function . 
 Of the three vitamins, folic acid60  is the main vitamin playing vital 
regulatory role in homocysteine metabolism and strongest determinant of  
plasma homocysteine level in CKD patients . Study conducted have shown 
that only folic acid containing therapy is able to lower the plasma 
homocysteine level in chronic renal failure patients .  Cobalamin is found to 
be effective only when Vit B 12 level is low. 
 Vit B6  found no significant effect on fasting plasma homocysteine level . 
Some studies point toward  the presence of serine deficiency as a 
contributing factors in development of hyperhomocysteinemia as it is 
contributing in both transulfuration and in the folate cycle and serine level 
found low in chronic renal failure patients . Betain dependent remethylation 
defect also possible for hyperhomocysteinemia  
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But in CKD patient betain level found to be normal and treatment with 
betain alone or added to folic acid found not to reduce homocysteine level . 
Till now so specific genetic 61 defect responsible  for hyperhomocysteinemia 
in  chronic renal failure patient has been identified . Those patient in which 
there is defect in 5, 10 methyl tetrahydrofolate reductase with CKD have 
found higher level of homocysteine than isolated defect in enzyme without 
renal dysfunction . 
Oral methionine and homocysteine  loading and stable isotope test have 
shown the possibility of third mechanism of hyperhomocysteinemia. 
To elucidate62 exact cause of hyperhomocysteinemia in patients with CKD 
patients several studies involving methionine , homocysteine loading test , 
stable isotope test were conducted . According to this , patients with CKD 
after oral  methionine loading test exhibit exaggerated plasma homocysteine 
level suggesting a transulfuration defect . In hemodialysis patients post 
methionine loading plasma homocysteine was mainly due to deficiency of 
serum folate not due to Vit B 12or Vit B 6 . Folate therapy lowered both 
fasting and post methionine homocysteine level indicating impairement of 
folate dependent remethylation defect in chronic renal failure and 
interdependency between methylation and transulfurtion . 
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After a homocysteine loading orally ,renal failure patients exhibited three to 
four fold increase in the plasma homocysteine half life compared with 
normal patients . 
Stable isotope study 63conducted to quantitatively assess whole body 
transmethylation , remethylation ,transulfuration  have shown strongly 
towards defective total body remethylation as the reason for increased 
homocysteine level  in kidney failure patients . Pathogenesis of this process 
of  impairement is not known . But presumed to be due to direct inhibitory 
effects of  uremic toxin or to an altered folate metabolism in uremia . 
Homocysteine lowering trials  in Chronic kidney disease patients  
         Continuous  efforts  are  being done to decrease homocysteine level in 
spatients with renal failure many studies are conducted .Results of those 
studies have shown that in contrast to normal people in renal failure patients 
hyperhomocysteinemia is often  resistant to all available treatment  like folic 
acid , Vit B 12 , Vit B6, betain , serine . This was seen uniformly in all 
patients with CKD . Refractoriness increases as renal function deteriorates . 
Hyperhomocysteinemia in CKD patients frequently becomes normal with 
supraphysiological doses of folic acid such as 2 to 15 mg per day. These 
were basesd on study in dialysis and renal transplant patient  who are often 
found to have low folate and other vitamin levels . 
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This causes some kind of confounding in treatment of CKD patients with 
increased homocysteine . Patient with end stage renal disease will respond 
to supraphysiological doses of vitamins which show that even in ESRD 
some functions of kidney are maintained and that is the reason they  respond 
to high doses but in an attenuated manner .Alternatively uremic solutes 
effectively inhibit extrarenal metabolism . 
Studies are concentrated towards presence of  genetic pomorphism in 
patients with CKD  which are contributing to increased homocysteine level  
particularly methylenetetrahydrofolate thermolabile  64 mutation . These 
studies have shown presence of hyperhomocyasteinemia only in presence of 
low folate level . 
Other studies by Ziad A Massy65 in his article therapy of homocysteinemia 
in chronic renal failure patients states that folic acid therapy in patients with 
CKD has shown to reduce but not normalizing the increased homocysteine 
level .Resistance to folate therapy shows that correlation between folic acid 
and homocysteine  only partial .Routine 1mg folic acid treatment often 
ineffective in patients with CKD . Oral supplementation of folic acid with 
very high doses around 15mg daily causing 20 to 50 fold increase in plasma 
folate concentration only partially correcting homocysteine level. 
Mechanism of resistance is not due to defective absorption or due to 
defective conversion into active form 5 – methyl tetrahydrofolate . 
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Alternatively reduced forms of folic acid which are metabolically more 
active than naïve folic acid was not associated with decreased homocysteine 
level to larger extent . Folic acid supplementation did not increase 
homocysteine clearance in CKD patients . Interpretation of all these study 
findings are eventhough folic acid  increases homocysteine remethylation in 
tissues and decreases export of homocysteine from tissues into plasma 
compartment it is not possible to overcome the primary defect of reduction 
in homocysteine clearance from plasma . 
Other mechanism which  causes resistance to treatment in patients with 
CKD are resistance to Vit B 12  causing abnormalities of remethylation 
pathway .Elian  and Hoffer found that by administering physiological doses 
of Vit B12(1mg per week) in patients with CKD on hemodialysis   who 
were already receiving folate 5 to 6mg per day and vitamin B6 5mg per day 
to increase concentration of Vit B 12 TO 50 to  60 fold showed to decrease 
the plasma homocysteine level by 32 % less than the lowest lowel attained 
by treatment with high doses of folate and pyridoxine . 
Homocysteine in CKD Patients and dialysis 66: 
       Accumulation of uremic toxins  and decrease in homocysteine 
clearance and metabolism due to decreased functioning kidney mass are 
main cause of hyperhomocysteinemia in dialysis patients .Some studies 
have pointed that patients with CKD without dialysis are found to respond 
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to therapy with folic acid in contrast to those who are on dialysis. It depends 
on type of dialysis and dialyser used . Most efficient dialyser remove uremic 
toxins and homocysteine and improves outcome .  
Low flux dialyzers67 are unable to remove sufficient toxins and 
homocysteine . High flux dialyzers are also found not to decrease 
homocysteine level to much extent . In contrast superflux mode significantly 
decreased homocysteine level compared with high flux mode .This may be 
due to removal of albumin with which homocysteine in bound . Recent 
study show that patients who are  undergoing daily nocturnal hemodialysis 
are found to have low homocysteine values compared to those with routine 
hemodialysis . This effect was supposed to be due to better removal of small 
and middle molecules in nocturnal hemodialysis patients . 
Studies are going on to displace bound  homocysteine  by using N acetyl 
cysteine  before hemodialysis 68 and subsequent removal using hemodialysis 
.Acute intravenous infusion of  NAC 69 5gm in 5% dextrose over 4 hours  
during a hemodialysis  session can displace bound homocysteine and was 
able to normalize total homocysteine concentration at the end of dialysis 
session with residual effect up to two days . Even though this approach was 
found useful, long term safety and efficacy of NAC need to be evaluated 
before drawing definite conclusion . On the other hand long term oral NAC 
at 1.2gm two times daily was not found to reduce homocysteine level in 
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dialysis patients  . This area of removal of homocysteine 70using dialysis 
with additional use of NAC is an areas of research aimed at decreasing 
homocysteine level and treatment strategy needs further  studies   
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MATERIALS AND METHODS 
PLACE OF STUDY :  
                                Thanjavur medical college and hospital ,Thanjvur  
TYPE OF STUDY:  
                                Single centred Prospective and observational  
PERIOD OF STUDY :  
                                Study conducted during a period of 8 months from 
January 2014 to August 2014 
ETHICAL COMMITTEE APPROVAL   :  
                                 Present study conducted was approved by institutional 
ethical committee :  
COLLABORATING DEPARTMENT : 
                                Department of General medicine and department of 
nephrology  
CONSENT: 
                                Informed consent was  obtained from the patient to 
participate in this study 
SAMPLE SIZE: 
                               50 patients of chronic kidney disease who admitted to 
Thanjavur medical college and hospital were chosen for study meeting 
inclusion and exclusion criteria  
SELECTION OF PATIENTS  : 
                              50 patients satisfying following inclusion criteria and not 
having exclusion criteria were taken up for the study  
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INCLUSION CRITERIA : 
                   Patients with 
                         1.Elevated blood urea and serum creatinine 
                         2. Ultrasound abdomen showing  features of chronic kidney 
disease  
EXCLUSION CRITERIA : 
              Patients  with 
1. Acute kidney injury 
2. Patients who are current smokers 
3. Patients who are current alcoholics 
4. Patients who are known case of chronic liver disease 
5. Patients who are having diabetes mellitus  
 
STUDY METHOD  : 
50 patients with chronic kidney disease who are admitted in 
Thanjavur medical college for symptoms related to chronic kidney disease 
or other reasons are selected for this study . Personal characteristics like  
age, sex , weight height, address were noted . Patients were enquired for 
presence of family history of chronic kidney disease or whether patient is 
undergoing dialysis for the chronic kidney disease, presence or absence of 
diabetes mellitus , systemic hypertension , chronic liver disease , smoking 
habits or alcohol consumption . General and systemic examinations done  
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INVESTIGATIONS : 
                                          Random blood sugar  
                                          Blood urea ,serum creatinine  
                                          Serum sodium , potassium 
                                           Complete hemogram 
                                          Liver function test  
                                          Eletrocardiogragh 
                                          Ultrasonography abdomen  
                                          Plasma homocysteine 
                                          Glomerular filtration rate (calculated ) 
 
 Fasting Plasma homocysteine were measured by flouroscein polarization 
immunoassay 
Obtained data and results are analysed by calculating percentage mean 
values standard deviation and standard error using T Test  , chi –square test. 
All statistical calculations are done using the software SPSS  for windows 
14 evaluation version and conclusion drawn  
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OBSERVATION AND RESULTS  
 
Age wise distribution of patients : 
                           Of the 50 patients of chronic kidney disease selected 
majority of patients were in age group between 41 to 60  years . From this 
table it is pbvious that as age increases the incidences and prevalences of 
people suffering from chronic kidney disease increases. But because of 
limited sample size exact prevalences  among different age group cannot be 
arrived . As age increases the functioning nephron number decreases leading 
to chronic kidney disease(table.1)  
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Age distribution of patients : 
 
Table 1 
Age Number of patients  Percentage 
<20 1 2% 
21-30 1 2% 
31-40 4 8% 
41-50 13 26% 
51-60 21 42% 
>60 10 20% 
 
 
 
 
Figure 1 
 
2% 2%
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26%
42%
20%
Age distribution of patients 
<20
21-30
31-40
41-50
51-60
>60
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Sex distribution of patients : 
 
                               Of  the patients selected for the study 37 patients were 
males and 13 patients  were females (table 2,figure 2) 
Table 2 
Males 37 74% 
Females 13 26% 
 
 
 
                    
 
Figure 2 
  
74%
26%
Sex distribution of patients 
males
females 
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Staging of CKD according to creatinine clearance and 
glomerular filtration rate as calculated by cockcroft gault 
formula : 
                  Of the patients selected majority of patients in CKD stage 4 and 
5  constituting around 94 percentage (table 3 , figure 3) 
Table 3 
Stage of CKD Number of patients Percentage 
0 0 O 
1 O O 
2 0 0 
3 3 6 
4 11 22 
5 36 72 
                    
 
Figure 3 
0
0
0
6%
22%
72% stage 5 CKD
stage 0
stage 1
stage 2
stage 3
stage 4
stage 5
CKD stage wise distribution of patients  
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HYPERHOMOCYSTEINEMIA: 
  Of the 50 patients in the study 39 patients found to be having elevated 
plasma Homocysteine values constituting around 78% (table 4,figure 4) 
Table 4 
Sex Total number Normal HCY HyperHCY Percentage hyper HCY 
Males 37 9 28 75% 
Females 13 2 11 84% 
  
 
 
Figure 4 
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Stage of CKD and elevated homocysteine level: 
 
If we compare plasma homocysteine level with corresponding glomerular 
filtration rate and stage of CKD  it shows that as patient deteriorates to next 
lower level of chronic kidney disease incidence of hyperhomocystenemia 
increases . Here in this study  we observed that in stage 4 and stage 5  of 
chronic kidney disease incidence of hyperhomocysteinemia were 72% and 
96.67 percentage respectively. 
Table 5 
Stage of 
CKD 
Number of 
patients 
Normal 
HCY 
Hyperhomo 
Cystenemia 
Percentage of 
hyperhomocystenemia 
0 o 0 0 0 
1 0 0 0 0 
2 0 0 0 0 
3 3 1 2 66.6% 
4 11 3 8 72.72% 
5 36 7 29 80.55% 
 
 
Figure 5 
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ECG  finding in CKD patients with normal and increased homocysteine 
level : 
We  observed that majority of patients were having abnormal 
electrocardiograph  indicating majority of patients with Chronic kidney 
disease were having some kind of cardiac diseases emphasizing the fact that 
cardiovascular diseases  are main causes of morbidity and mortality in CKD 
patients . Majority were having left ventricular  hypertrophy , may be 
because of increased prevalence of hypertension in patients with Chronic 
kidney disease  . Of the 50 patients selected for the study 47 patients were 
having abnormal electrocardiograph  constituting 94%   . In those  with 
hyperhomocysteinemia  only three were found to have normal ECG . All 
others were having abnormal ECG (table 6 ,figure 6) 
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Table 6 
ECG 
HOMOCYSTEINE 
NORMAL INCREASED 
11 39 
NORMAL 
0 3 
  
ABNORMAL 11 36 
PERCENTAGE 
OF 
ABNORMAL 
ECG 
100% 92.6% 
 
 
Figure 6 
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Hyperhomocysteinemia is classified into  
                                   Mild , level between 15 -30 umol/lite  
                                   Moderate   31- 100 umol/litre  
                                   Severe   > 100 umol/litre .  
  In our study in those having hyperhomocysteinemia majority are falling in 
the group of mild hyperhomocysteinemia . Of the 39 patients with 
hyperhomocysteinemia 37 patients were in the group of mild 
hyperhomocysteinemia . Only two were found to have moderate 
hyperhomocysteinemia .(table 7, figure 7) 
Table 7 
Hyperhomocysteinemia Numbers Percentage 
Mild 37 94.87% 
Moderate 2 5.1% 
Severe 0 0% 
 
 
Figure 7 
 
94.87%
5.10%
Hyperhomocysteinemia  severity in percentage 
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MODERATE
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 In our study there were 7 patients with CKD were on intermittent 
hemodialysis or peritoneal dialysis . But all were found to have mild 
hyperhomocystinemia  
We excluded the patients with diabetes mellitus because diabetes itself can 
increase  the homocysteine by other mechanisms .So it may act as a 
confounding factor . 
In our study we found that of the 50 patients selected for study 35 had 
hypertension . Of the 35 patients 27 had elevated homocysteine level . 
Those without hypertension were 15 patients . Among them 12 had elevated 
homocysyeine level (table 8, figure 8) 
Table 8 
Hypertension                 Homocysteine  
Normal(11)  Elevated (39) 
Present  8(72.7%) 27(69.2%) 
Absent  3(27.2%) 12(30.7%) 
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Figure 8 
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                     Statistical analysis of this study: 
Frequency Table 
Age (years) 
Particulars No.of respondents (n=50) 
Percentage 
(100%) 
Below 40yrs 6 12.0 
41 to 50yrs 13 26.0 
51 to 60yrs 21 42.0 
61 to 70yrs 8 16.0 
71yrs & above 2 4.0 
Sex  
Particulars No.of respondents (n=50) 
Percentage 
(100%) 
Male 37 74.0 
Female 13 26.0 
Weight(Kg)  
Particulars No.of respondents (n=50) 
Percentage 
(100%) 
40 to 49kgs 10 20.0 
50 to 59kgs 16 32.0 
60 to 69kgs 14 28.0 
70 to 79kgs 9 18.0 
80kgs & above 1 2.0 
 
Diabetes mellitus  
Particulars No.of respondents (n=50) 
Percentage 
(100%) 
Absent 50 100.0 
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SHT  
Particulars No.of respondents (n=50) 
Percentage 
(100%) 
Absent 15 30.0 
Present 35 70.0 
 
ECG  
Particulars No.of respondents (n=50) 
Percentage 
(100%) 
No 3 6.0 
Ab 47 94.0 
 
on dialysis  
Particulars No.of respondents (n=50) 
Percentage 
(100%) 
No 43 86.0 
Yes 7 14.0 
 
GFR(ml/min)  
Particulars No.of respondents (n=50) 
Percentage 
(100%) 
Less than 15 35 70.0 
15 to 29 12 24.0 
30 to 59 3 6.0 
 
Homocysteine (umol/lt)  
Particulars No.of respondents (n=50) 
Percentage 
(100%) 
Negative 11 22.0 
Positive 39 78.0 
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Descriptive Statistics 
Item  Min. Max. Mean  S.D 
Age(years) 18 75 53.10 11.151 
Weight(Kg) 40 100 57.82 11.549 
Urea(mg%) 60 204 113.66 32.128 
Creatinine(mg%) 2.00 22.20 7.4380 4.47984 
GFR(ml/min) 2.43 33.46 12.8300 6.95518 
Homocysteine(umol/lt) 9.34 58.00 19.6740 7.83157 
Chi-square test  
Homocysteine(umol/lt) 
Age(years
) 
Negative Positive Total Statistica
l 
inference 
(n=11
) 
(100%
) 
(n=39
) 
(100%
) 
(n=50
) 
(100%
) 
Below 
40yrs 1 9.1% 5 12.8% 6 12.0% 
X2=1.427 
Df=4 
.840>0.05 
Not 
Significan
t 
41 to 
50yrs 2 18.2% 11 28.2% 13 26.0% 
51 to 
60yrs 5 45.5% 16 41.0% 21 42.0% 
61 to 
70yrs 2 18.2% 6 15.4% 8 16.0% 
71yrs & 
above 1 9.1% 1 2.6% 2 4.0% 
Chi-square test  
Homocysteine(umol/lt) 
Sex Negative Positive Total Statistical inference (n=11) (100%) (n=39) (100%) (n=50) (100%) 
Male 9 81.8% 28 71.8% 37 74.0% X2=.448 
Df=1 
.503>0.05 
Not 
Significant 
Female 2 18.2% 11 28.2% 13 26.0% 
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Chi-square test  
Homocysteine(umol/lt) 
Weight(Kg
) 
Negative Positive Total Statistica
l 
inference 
(n=11
) 
(100%
) 
(n=39
) 
(100%
) 
(n=50
) 
(100%
) 
40 to 49kgs 1 9.1% 9 23.1% 10 20.0% X2=7.657 
Df=4 
.105>0.05 
Not 
Significan
t 
50 to 59kgs 5 45.5% 11 28.2% 16 32.0% 
60 to 69kgs 1 9.1% 13 33.3% 14 28.0% 
70 to 79kgs 3 27.3% 6 15.4% 9 18.0% 
80kgs & 
above 1 9.1% 0 .0% 1 2.0% 
Chi-square test  
Homocysteine(umol/lt) 
DM Negative Positive Total Statistical inference (n=11) (100%) (n=39) (100%) (n=50) (100%) 
Absent 11 100.0% 39 100.0% 50 100.0% - 
Chi-square test  
Homocysteine(umol/lt) 
SHT Negative Positive Total Statistical inference (n=11) (100%) (n=39) (100%) (n=50) (100%) 
Absent 2 18.2% 13 33.3% 15 30.0% X2=.938 
Df=1 
.333>0.05 
Not 
Significant 
Present 9 81.8% 26 66.7% 35 70.0% 
 
 
 
 
 
                                                 
99 
 
 
Chi-square test  
Homocysteine(umol/lt) 
ECG Negative Positive Total Statistical inference (n=11) (100%) (n=39) (100%) (n=50) (100%) 
No 0 .0% 3 7.7% 3 6.0% X2=.900 
Df=1 
.343>0.05 
Not 
Significant 
Ab 11 100.0% 36 92.3% 47 94.0% 
Chi-square test  
Homocysteine(umol/lt) 
on 
dialysis 
Negative Positive Total Statistical 
inference (n=11) (100%) (n=39) (100%) (n=50) (100%) 
No 11 100.0% 32 82.1% 43 86.0% X2=2.296 
Df=1 
.130>0.05 
Not 
Significant 
Yes 0 .0% 7 17.9% 7 14.0% 
Chi-square test  
Homocysteine(umol/lt) 
GFR(ml/mi
n) 
Negative Positive Total Statistica
l 
inference 
(n=11
) 
(100%
) 
(n=39
) 
(100%
) 
(n=50
) 
(100%
) 
Less than 15 7 63.6% 28 71.8% 35 70.0% X2=.369 
Df=2 
.831>0.0
5 
Not 
Significa
nt 
15 to 29 3 27.3% 9 23.1% 12 24.0% 
30 to 59 1 9.1% 2 5.1% 3 6.0% 
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Chi-square test  
GFR(ml/min) 
Age(yea
rs) 
Less than 
15 15 to 29 30 to 59 Total 
Statisti
cal 
inferen
ce 
(n=3
5) 
(100
%) 
(n=1
2) 
(100
%) 
(n=
3) 
(100
%) 
(n=5
0) 
(100
%) 
Below 
40yrs 5 
14.3
% 1 8.3% 0 .0% 6 
12.0
% X2=3.4
17 
Df=8 
.906>0.
05 
Not 
Signific
ant 
41 to 
50yrs 10 
28.6
% 3 
25.0
% 0 .0% 13 
26.0
% 
51 to 
60yrs 14 
40.0
% 5 
41.7
% 2 
66.7
% 21 
42.0
% 
61 to 
70yrs 5 
14.3
% 2 
16.7
% 1 
33.3
% 8 
16.0
% 
71yrs & 
above 1 2.9% 1 8.3% 0 .0% 2 4.0% 
Chi-square test  
GFR(ml/min) 
Sex 
Less than 15 15 to 29 30 to 59 Total Statistic
al 
inferen
ce 
(n=3
5) 
(100
%) 
(n=1
2) 
(100
%) 
(n=
3) 
(100
%) 
(n=5
0) 
(100
%) 
Male 24 68.6% 10 
83.3
% 3 
100.0
% 37 
74.0
% 
X2=2.13
3 Df=2 
.344>0.
05 
Not 
Signific
ant 
Fema
le 11 
31.4
% 2 
16.7
% 0 .0% 13 
26.0
% 
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Chi-square test  
GFR(ml/min) 
Weight(
Kg) 
Less than 
15 15 to 29 30 to 59 Total 
Statisti
cal 
inferen
ce 
(n=3
5) 
(100
%) 
(n=1
2) 
(100
%) 
(n=
3) 
(100
%) 
(n=5
0) 
(100
%) 
40 to 
49kgs 9 
25.7
% 1 8.3% 0 .0% 10 
20.0
% X2=14.
887 
Df=8 
.061>0.
05 
Not 
Signific
ant 
50 to 
59kgs 13 
37.1
% 3 
25.0
% 0 .0% 16 
32.0
% 
60 to 
69kgs 8 
22.9
% 3 
25.0
% 3 
100.0
% 14 
28.0
% 
70 to 
79kgs 5 
14.3
% 4 
33.3
% 0 .0% 9 
18.0
% 
80kgs & 
above 0 .0% 1 8.3% 0 .0% 1 2.0% 
Chi-square test  
GFR(ml/min) 
DM 
Less than 15 15 to 29 30 to 59 Total Statisti
cal 
inferen
ce 
(n=3
5) 
(100
%) 
(n=1
2) 
(100
%) 
(n=
3) 
(100
%) 
(n=5
0) 
(100
%) 
Abse
nt 35 
100.0
% 12 
100.0
% 3 
100.0
% 50 
100.0
% - 
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Chi-square test  
GFR(ml/min) 
SHT 
Less than 15 15 to 29 30 to 59 Total Statistic
al 
inferen
ce 
(n=3
5) 
(100
%) 
(n=1
2) 
(100
%) 
(n=
3) 
(100
%) 
(n=5
0) 
(100
%) 
Abse
nt 12 
34.3
% 1 8.3% 2 
66.7
% 15 
30.0
% 
X2=4.90
9 Df=2 
.086>0.
05 
Not 
Signific
ant 
Prese
nt 23 
65.7
% 11 
91.7
% 1 
33.3
% 35 
70.0
% 
 
                                                        Chi-square test  
GFR(ml/min) 
EC
G 
Less than 15 15 to 29 30 to 59 Total Statistic
al 
inferenc
e 
(n=3
5) 
(100
%) 
(n=1
2) 
(100
%) 
(n=
3) 
(100
%) 
(n=5
0) 
(100
%) 
No 1 2.9% 1 8.3% 1 33.3% 3 6.0% 
X2=4.70
3 Df=2 
.095>0.0
5 
Not 
Signific
ant 
Ab 34 97.1% 11 
91.7
% 2 
66.7
% 47 
94.0
% 
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Chi-square test  
GFR(ml/min) 
on 
dialy
sis 
Less than 
15 15 to 29 30 to 59 Total 
Statisti
cal 
inferen
ce 
(n=3
5) 
(100
%) 
(n=1
2) 
(100
%) 
(n=
3) 
(100
%) 
(n=5
0) 
(100
%) 
No 31 88.6% 9 
75.0
% 3 
100.0
% 43 
86.0
% 
X2=1.88
7 Df=2 
.389>0.
05 
Not 
Signific
ant 
Yes 4 11.4% 3 
25.0
% 0 .0% 7 
14.0
% 
 
 Chi-square test  
 GFR(ml/min) 
Homocysteine
(umol/lt) 
Less than 
15 15 to 29 30 to 59 Total 
Statist
ical 
infere
nce 
(n=
35) 
(100
%) 
(n=
12) 
(100
%) 
(n=
3) 
(100
%) 
(n=
50) 
(100
%) 
Negative 7 20.0% 3 
25.0
% 1 
33.3
% 11 
22.0
% 
X2=.3
69 
Df=2 
.831>0
.05 
Not 
Signifi
cant 
Positive 28 80.0% 9 
75.0
% 2 
66.7
% 39 
78.0
% 
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Paired Samples ‘t’-test 
Item  Mean S.D Mea
n 
S.D T Df 
Statisti
cal 
inferen
ce 
GFR(ml/min) (n=50) 12.8300 
6.955
18 -6.84
40 
11.465
62 
-
4.2
21 
4
9 
.000<0.
05 
Signific
ant 
Homocysteine(umol/lt
)(n=50) 
19.67
40 
7.831
57 
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DISCUSSION 
Recently  disulfur aminoacid homocysteine has gained much importance 
because of  its role in vascular thrombosis and  genesis of atherosclerosis . 
Chronic kidney disease is also very much prevalent in the general 
population .  The patients with CKD are very much susceptible to 
cardiovascular system involvement related morbidity and mortality. As 
recent studies have shown an increased prevalence of 
hyperhomocysteinemia  in CKD patients we tried to conduct a study on this 
. 
Recent articles and publication in internet shows that chronic kidney disease 
is associated with hyperhomocysteinemia and significantly contributes to 
cardiovascular morbidity and mortality .  
Menon et al , in their study found that hyperhomocysteinemia was prevalent 
in 56% 0f  CKD patients they studied , and hyperhomocysteinemia was 
partly amenable to treatment with  vitamins in stages 3  &  4 
In this sudy we found that 78% of CKD patients were having 
hyperhomocysteinemia correlating with other studies conducted elsewhere 
in the world and hyperhomocysteinemia was more prevalent as stages of 
CKD increases . Even though our study sample size was smaller  we found 
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that hyperhomocysteinemia was more prevalent in later stages of CKD. It 
was in accordance with the concept that as renal function deteriorates the 
homocysteine excretion decreases and its level increases in plasma .   
We even noted  in the study that even if the patient was on dialysis  it was 
not affecting the homocysteine level elevation as mentioned in other review 
literature that homocysteine level will transiently decreases after a dialysis 
session  but swings back to normal within two to three days to predialysis 
value .  
We observed that majority of patients with CKD had some kind of  ECG 
abnormality correlating well with statement that cardiovascular  morbidities 
are most important cause of mortality in patients  with CKD  . Our main 
concern to evaluate for the presence or absence of hyperhomocysteinemia in 
CKD patients was to decrease the cardiovascular morbidity and mortality . 
So its worthy to take measures to decrease homocysteine levels in patients 
with CKD .   
We tried in all ways to exclude confounding factors like diabetes , smoking , 
chronic alcoholism, chronic liver disease which are independently 
associated with hyperhomocysteinemia .    
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 Regarding the sexual difference in hyperhomocysteinemia  any definite 
conclusion cannot be drawn as there are discrepancies among the sample 
size and sex proportion  
We could not exclude the other genetic variations which may affect the 
homocysteine level . We even could not measure the levels of Vit B12 and 
Folic acid , Pyridoxine level in patients with CKD  due to financial 
restriction . 
Levels of Vitamin B12 and Folic acid in CKD patients to correct  
hyperhomocysteinemia is more as compared with patients without CKD . So 
it is advisable to supplement more amount of vitamins to correct 
hyperhomocysteinemia in CKD patients to prevent cardiovascular morbidity 
and mortality. 
Further studies involving larger sample size with measurement vitamin 
levels along with genetic studies are required to exactly elucidate the 
incidence and prevalence  of hyperhomocysteinemia in Chronic kidney 
disease patients and large cohort studies to demonstrate exact correlation 
between hyperhomocysteinemia and cardiovascular morbidity and mortality  
and treatment strategy aimed at decreasing hyperhomocysteinemia to reduce 
cardiovascular morbidity and mortality is necessary 
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LIMITATIONS OF THIS  STUDY  
1. Limited sample size  
2.  Levels of Vitamin B12  and folic acid are not measured  
3. Sample distribution is not uniform among CKD patients so as to exactly 
correlate between decreased renal function and level of 
hyperhomocysteinemia  
4. Genetic aspects of  disease not emphasized much 
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CONCLUSION  
Hyperhomocysteinemia was observed in 78 % of patients with CKD  
 Prevalence of hyperhomocysteinemia was more in End stages of CKD 
(stage 3 & 4 &5) 
Homocysteine   elevation  was found  in both CKD without dialysis and 
with  intermittent hemodialysis or peritoneal dialysis. 94.87 % of patients  
with CKD were found to have  mild hyperhomocysteinemia  and  5.1% had 
moderate hyperhomocysteinemia and  none had severe 
hyperhomocysteinemia  
Eventhough we observed hyperhomocysteinemia  in 78 % of patients we 
tested ,further studies involving larger sample size and excluding  other risk 
factors for hyperhomocysteinemia  is required to validate this results . 
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Proforma for dissertation on chronic kidney disease  and 
plasma homocysteine level  
Name :                                  age  :             sex:             IP Number:                  
address  
Weight  :                         Height : 
Presenting complaints :    
  
Family history of kidney diseases:  yes /no  
Whether patient is on dialyasis     :      yes /no  
 Whether  patient is k/c/o               :   SHT / Diabetes / CAHD / Chronic liver 
disease /             
                                                                                                                               
alcoholic /smoker                                                        
 Treatment/drugs  patient receiving : 
Examination findings  
                  Gneral physical examination :                                                      
                    vitals : 
                                                 
 
 
                  Systemic examination            
                              Cardiovascular system  
                             Respiratory system  
                             Abdomen  
                              Central nervous system  
Investigation : 
                                              Day 1       Day 2      Day 3     
 RBS 
 BLOOD UREA                                                                            
SERUM CREATINE 
Na+ 
K+                                                                                      
COMPLETE  HEMOGRAM  
  
LIVER FUNCTION TEST  
 
 
                                                 
 
 
 
URINE ROUTINE  
ECG   
USG   ABDOMEN 
PLASMA   HOMOCYSTEINE  
GLOMERULAR FILTRATION  RATE  (calculated ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
 
 
 
 
CONSENT FORM 
I __________________________________________  hereby give  consent 
to participate in the study conducted by Dr.ADARSHA.G.K , post graduate 
in department of internal medicine ,Thanjavur medical college & hospital, 
Thanjavur – 613004 and to use my personal clinical data and result of 
investigation for the purpose of analysis and to study the nature of disease. I 
also give consent for further investigations 
 
 
Place : 
Date :       Signature of participant 
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1 kathayee 32296 60 F 45 A A 102 5.5 Ab N 7.72 14.63
2 seeman raj 40955 35 M 50 A A 160 9.8 Ab N 7.44 15.57
3 kaliyaperumal 40814 60 M 60 A P 100 3.7 Ab N 16.57 21.72
4 anjalai 40246 58 F 60 A P 150 9.2 Ab N 12.6 24.45
5 kannan 39376 50 M 50 A P 150 9.2 Ab Y 7.35 18.5
6 kaliyaperumal 38185 47 M 60 A P 150 13.8 Ab Y 4.93 15.45
7 kamalambal 37967 75 F 75 A P 150 6.4 Ab N 9.4 12.27
8 selvaraj 40244 55 M 75 A P 96 6.9 Ab N 13.02 33.58
9 palanisamy 40251 64 M 70 A A 128 10.8 Ab N 6.84 22.17
10 siddique 39539 34 M 70 A P 154 15.7 Ab N 6.77 11.42
11 perumal 40233 70 M 70 A P 87 5 Ab N 15.55 23.71
12 elangovan 37484 54 M 60 A P 138 8.8 Ab N 7.96 18.51
13 parimalam 38113 44 F 50 A A 112 9.9 N N 6.73 16.23
14 panduranga 41327 60 M 50 A P 88 3.6 Ab N 15.43 10.58
15 kalaimani 40056 28 F 60 A P 142 12.8 Ab N 6.36 26.98
16 ravichandran 40844 52 M 100 A P 108 4.7 Ab N 26 9.62
17 paramayyan 40895 48 M 50 A A 70 8.1 Ab Y 8.24 17.43
18 manimegalai 40465 55 M 45 A A 94 5 Ab N 10.06 17.85
19 ramaraj 39796 51 M 45 A A 88 4.5 Ab N 12.36 21.99
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20 mathivanan 40209 61 M 60 A P 78 2 Ab N 33.46 13.86
21 ramaiyan 30076 60 M 45 A P 84 3.2 Ab N 15.62 18.28
22 govindaraj 38846 60 M 60 A A 60 2 Ab N 30.48 18.17
23 ayyakannu 38878 55 F 40 A A 88 3.8 Ab N 12.42 27.94
24 selvaraj 41466 44 M 65 A P 132 10.5 Ab Y 8.25 25.28
25 selvaraj 41354 58 M 60 A P 180 14 Ab Y 15.2 24.91
26 Gandhi 42076 48 F 45 A P 148 8.3 Ab N 6.92 19.88
27 ummusulma 41758 55 F 68 A P 130 8.8 Ab N 9.14 24.14
28 Manobalan 42008 18 M 52 A P 172 22.2 Ab N 3.96 22.36
29 Kaveri 41914 66 F 70 A P 120 3.9 Ab Y 18.4 16.76
30 Muthusamy 83714 68 M 45 A P 78 3.2 Ab N 14.61 15.58
31 Murugaiyan 83814 65 M 50 A P 74 3.9 Ab N 13.35 14.44
32 Soundarraj 41924 52 M 54 A A 132 12.6 Ab N 5.36 13.27
33 Alagammal 41984 54 F 50 A P 204 20.5 Ab N 2.43 29.08
34 Thangarasan 41850 65 M 58 A P 122 4.3 Ab N 14.05 18.24
35 Rajendran 40015 52 M 52 A A 92 5 Ab N 11.6 22.8
36 Rajendran 40845 51 M 50 A A 120 6.8 Ab N 13.1 26.18
37 Ramasamy 32323 50 M 60 A P 114 6.8 Ab N 11.1 19.58
38 Veearmay 43346 47 M 60 A P 112 2.9 Ab Y 26.72 16.01
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39 Muthu 48346 60 M 60 A A 60 2.7 N N 30 17.44
40 Rangasamy 40386 47 M 48 A P 114 9.8 Ab N 6.6 15.32
41 Jayakanndan 39253 50 M 50 A P 88 4.3 Ab N 15.9 24.69
42 Sanyasimuthu 40392 75 M 75 A P 88 3.8 Ab N 17.8 19.53
43 Thangaponnu 29766 50 F 48 A P 80 3.8 Ab N 13.41 17.09
44 Subramaniyam 29876 48 M 75 A P 100 4.5 Ab N 21 9.82
45 kaliyaperumal 40392 62 M 78 A P 98 8.4 Ab N 10.05 58
46 Rajagopal 17152 60 M 45 A P 93 4.9 Ab N 10.2 15.16
47 Kathaiyan 36927 51 M 58 A P 110 8.1 Ab N 13.5 9.34
48 Rani 30987 40 F 50 A A 84 3.4 N N 17.9 18.15
49 Duraikannu 30894 49 M 55 A P 135 9.3 Ab N 9.47 12.11
50 Renugadevi 40025 34 F 60 A A 126 10.8 Ab N 8.17 27.63
F FEMALE
M MALE
A ABSENT
P PRESENT
Y YES
N NO
